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ABSTRACT
The Effects of Vitamin B6 Supplementation
on Premenstrual Symptoms
February, 1985
Kim Elizabeth Kendall, B.A.
,
University of California/Davis
M. S.
,
University of Massachusetts
Ph.D., University of Massachusetts
Directed by: Professor Bonnie Strickland
A double-blind controlled study of the effects of vitamin B6
supplementation on premenstrual symptoms was conducted. Fifty-six women
who reported moderate to severe premenstrual mood changes participated in
the study. Symptoms were monitored prospectively through daily home
recordkeeping over a one month baseline period and a two month treat-
ment period (3 months total). Subjects received daily supplements of
150 mg of vitamin B6 or the equivalent of a placebo over the entire two
month treatment period. Analysis of covariance and t-test comparison
results suggested that vitamin B6 may improve some premenstrual symptoms
(including dysphoria) during periods of increased stress. Vitamin B6 was
observed to have a general ability to improve subjective ratings of
concentration level regardless of menstrual cycle phase. Data
also sugges
ted that a placebo in capsule form may be more effective
than vitamin
B6 in tablet form in ameliorating premenstrual
symptoms. Future areas
of inquiry and methodological concerns are discussed.
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CHAPTER I
INTRODUCTION
For centuries the monthly hormonal cycling in women has been
associated with fluctuations in physical and psychological well-being.
Through the ages, the effects of menstrual changes have variously
influenced women in their cultures and legends. In this century,
scientific documentation of these phenomena has begun to accumulate.
For many women the monthly changes are associated with serious
difficulties. Recent reviews have cited the increased incidence of
psychiatric problems such as suicidal behavior and rate of hospitalizations
for women during the premenstrum (Abramowitz and Balar, 1982; Berlin,
Bergey and Money, 1982; Dalton, 1959; Jacobs and Charles, 1970; Smith,
1975; Steiner and Carroll, 1977), as well as increased criminal acts
(Dalton, 1980). Although for most women, premenstrual symptoms do not
require professional intervention, epidemiological evidence suggests
that from 70% to 90% of all women report recurrent premenstural symptoms,
and 20% to 40% of women experience some degree of temporary mental
or physical dysfunction premenstrually (Reid and Yen, 1981). The
premenstrual syndrome is widely variable among women. Some women become
tense and irritable, while others feel depressed and lethargic.
Physical
symptoms may include headache, backache, fatigue, swelling
and tender-
ness of breast or abdominal tissues, changes in appetite,
migraine,
1
2acne, seizures, and hypoglycemia (Smith, 1975; Reid and Yen, 1981).
The relationship between physical and psychological symptoms has yet
to be clarified; however, some researchers have recently attempted to
identify symptom patterns or clusters, combining both physical and
psychological symptoms (Endicott, Halbreich, Schacht and Nee, 1981;
Haskett, Steiner, Osmun and Carroll, 1980; Moos, 1968).
A variety of pituitary, adrenal, and ovarian hormones — at either
excessive or insufficient levels, or in improper balance — have been
implicated as possible causes of premenstrual disturbances. Estrogen,
progesterone, follicle stimulating hormone, luteinizing hormone, prolac-
tin, ACTH, Cortisol, and monoamine oxidase all show periodic changes in
blood level in relation to the menstrual cycle. Renin, angiotensin, and
aldosterone, which regulate body fluid blance, also fluctuate cycli-
cally (Steiner and Carroll, 1977). The elimination of ovarian cyclicity
through the administration of an agonist of gonadotropin-releasing
hormone was shown to markedly reduce physical and behavioral premenstrual
symptoms in a double-blind crossover study involving eight subjects
diagnosed as having PMS (Muse, Cetel, Futterman and Yen, 1984). Neverthe-
less, no identifiable endocrine or physiologic markers have been found
to distinguish women with the syndrome from those without (Reid and Yen,
1981). It is also clear that social, cultural, and psychological
factors
such as attitudes, expectancies, vulnerability to stress, and
life style
choice are salient factors which must be taken into account
in any
comprehensive investigation of this problem (Sherif, 1980).
3While interrelated functioning of many of these substances has been
documented in laboratory studies, the central mechanism leading to the
premenstrual syndrome continues to elude researchers. Accumulated
s research evidence suggests that this syndrome is related to a
dysfunction along the hypothalamic-pituitary-ovarian axis (Reid and
Yen, 1981). It seems possible that in such a complex system of
interacting substances and processes, the variety of premenstrual
symptoms could result from any number of possible systemic imbalances,
rather than from a single consistent underlying cause.
Because of the immediacy of the problem of widespread and debili-
tating premenstrual distress, it has been for many researchers and
clinicians at least as important to discover means to alleviate symptoms,
as it has been to identify underlying causes. Given the enormous
complexity and variety of causal patterns suggested by the accumulated
research, it is understandable that fruitful investigations of
appropriate treatments have been extremely difficult to accomplish.
Careful examination of the literature shows it to be frustratingly
inadequate. Many popular remedies for menstrual and premenstrual
distress have been untested or have been based on evidence from poorly
controlled or uncontrolled clinical trials (Smith, 1975). Yet, vast
numbers of women, with the collaboration of their physicians, subject
themselves to chemical remedies of unknown effectiveness which may
have serious side effects. Oral contraceptives, progesterone,
and
diuretic agents are three of the most widely used treatments,
but the
few well-controlled, double-blind studies in which these
have been
Astudied, have failed to demonstrate their effectiveness (Steiner and
Carroll, 1977). The possible risks of increased cancer and circulatory
disorders suspected with the use of synthetic hormones are well known.
Diuretics can have a variety of side effects, including depression
(Huapaya and Ananth, 1980) — one of the major symptoms associated with
the premenstrual syndrome. Given these cautions, it is of particular
importance to delineate treatments that are both safe and effective.
One of the main goals of this research was to develop a general
methodology suitable for studying the menstrual cycle, to begin the
delineation of particular variables that warrant further research,
and to develop a rigorously controlled method for testing alterna-
tive treatments for various premenstrual symptoms.
Nutritional treatments have become increasingly popular, as a
growing number of women prefer to avoid the use of drugs. Currently,
there is no way for these women to make informed decisions regarding
the effectiveness of nutritional treatments. Although it seems logical
that some form of dietary supplementation might ameliorate premenstrual
symptoms without the danger of side effects, very little controlled
research has been done to test its effectiveness. Perhaps the most
popular vitamin therapy for the premenstural syndrome currently involves
dietary supplements of pyridoxine (vitamin B6) . The purpose of this
research was to determine whether dietary supplements of vitamin B6
can exert a beneficial effect on premenstrual depression and
irritability
in particular. The rationale for this treatment will be
addressed later
in this paper. The following is intended to be a brief
review of
5major research directions regarding the premenstrual syndrome.
Overview of Regulation of the Menstrual Cycle
The brain controls the interacting activities of the hypothalamus,
pituitary, and ovaries, thereby controlling release of hormones. The
ovaries provide feedback signals to the brain-pituitary system which,
in turn, responds by adjusting the amount and type of hormone to be
released. Most menstrual disorders are commonly due to disturbances in
the brain-pituitary portion of this regulatory system. An understand-
ing of these interacting components is necessary in order to examine
physiological and psychological factors that may be involved in the
premenstural syndrome. This section is intended to summarize, in a
general way, the physiological processes which regulate a normal
menstrual cycle.
The average menstrual cycle lasts 28 days and begins on the first
day of menses (period of menstrual bleeding) . The first half of a
cycle is the follicular phase, and the luteal phase makes up the
second half. The follicular and luteal phases are divided by ovulation
which occurs at midcycle, or approximately at day number 14, and
again
are divided by the onset of the menses. The first half of
the follicular
phase includes the menses and the second half of this
phase begins on
the 6th or 7th day of the menstrual cycle (Yen, 1981).
Other authors
have chosen to further subdivide the luteal phase
into the early
luteal phase, late luteal, and premenstrual
periods (Rossi and Rossi,
1980); days 17-21, 22-2A, and 25-28, respectively
comprising these
subdivisions
.
6During the early follicular phase, the hypothalamus signals the
pituitary which, in turn, releases follicle stimulating hormone (FSH)
.
FSH encourages the follicles in the ovaries to begin to grow and
mature and produce estrogen. The second half of the follicular phase
is marked by an increase in the release of estradiol and esterone.
Estradiol rises slowly at first, and then rapidly to a peak, stimulating
the release of luteinizing hormone (LH) by the pituitary. One day
later, a peak surge of LH is seen which stimulates the rupture of a
follicle and the release of an ovum (egg). As estrogen levels rise,
FHS levels decrease. Several days before the surge of LH , levels of
androgens, testosterone and progesterone are also beginning to rise
due to increased activity in the follicles. Ovulation is accompanied
by an abrupt surge in LH-FSH, which lasts about 36 hours, followed by
release of the ovum 24 hours later. Once the ovum is released, LH
continues to influence the follicle to become the progesterone producing
corpus luteum (yellow body). Progesterone levels rise and estrogen
levels fall abruptly. Progesterone produced by the corpus luteum
stimulates the lining of the uterus to prepare for the implantation of
the ovum which is on its way via the fallopian tubes. Peak progesterone
levels are reached about 8 days after the LH surge. Parallel, but
smaller increases are seen in 17 * -hydroxyprogesterone , estradiol,
and
esterone, while LH and FSH continue to decline. The corpus
luteum has
a lifetime of about 14 days. (Interestingly, both estrogen
and proges-
terone produced by the luteal tissue seem to destroy
this same
tissue, forming a self-destruct mechanism.) If the
ovum is not
fertilized, or it is fertilized too late for it to develop sufficiently
by the time it reaches the uterus, it is unable to implant itself in the
lining of the uterus, leading to a decline in progesterone and a further
decline in estrogen in the late luteal phase. This decline may initiate
local production of prostaglandins, which are thought to promote
vasoconstriction, as well as other factors involved in the process of
sloughing off and expelling the lining of the uterus. At the end of the
luteal phase, or the beginning of the menses, FHS levels begin to rise
again to initiate the growth of the follicles for the next cycle
(Carlson, 1977; Yen, 1981).
Other factors have been linked to the premenstrual syndrome, because
they also fluctuate over the menstrual cycle. Cortisol levels are higher
during the follicular phase than the luteal phase. Aldosterone (an
electrolyte-regulating hormone of the adrenal cortex) is two times
higher during the luteal phase than the follicular phase, peaking the
9th or 10th day before menses and dropping rapidly 6 or 7 days before
menstrual bleeding begins (Steiner and Carroll, 1977). Corticosterone
and desoxycorticosterone show a similar pattern. Progesterones and
estrogens induce the formation of angiotensin which initiates and
parallels fluctuations in levels of aldosterone (Steiner and Carroll,
1977) .
It has been hypothesized that one or several of these factors
related to the normal menstrual cycle may be an imbalance and ,
therefore,
may be responsible for the premenstrual syndrome (IMS) .
The following
8is intended to be a review of the major theories of dysfunction which
physiologists have explored in relationship to the PMS
.
Estrogen Excess - Progesterone Deficiency
Since 1931, it has been proposed that an excess of estrogen might
be responsible for the PMS. More recently, reports have documented
increased levels of estrogen and decreased levels of progesterone on
women with the PMS (Backstrom and Carstensen, 1974; Munday , Brush and
Taylor, 1977, 1981). Unbalanced estrogen production could be
responsible for fluid retention, breast swelling, abdominal swelling,
abnormal carbohydrate metabolism, as well. as mood changes seen in
the PMS. Other studies have found that levels of estrogen and proges-
terone withdrawal, not an improper estrogen :progesterone ratio, might
be responsible for the PMS (Kutger and Brown, 1972). Although it was
thought that the administration of natural or synthetic progesterones
might, therefore, alleviate the PMS, there have been no large
double-blind studies demonstrating the usefulness of either progesterone
or testosterone therapy in treating the PMS (Reid and Yen, 1981; Smith,
1975) .
Treatment of the PMS with progesterone is still fairly popular in
clinics (Reid and Yen, 1981). Indirect evidence for the possible
effectiveness of progesterone therapy came with research on oral
contraceptives which showed that contraceptives which were highly
estrogenic made premenstrual symptoms worse and those that
were strongly
progesterogenic improved premenstrual dysphoria. Oral
contraceptives
9were reported to both lessen and worsen premenstrual symptoms.
Controlled studies by Coppen
,
Milne, Outram and Weber and by Jordheim
(see Steiner and Carroll, 1977) failed to confirm the effectiveness of
oral contraceptives in treating the PMS
.
Synthetic progesterones
,
when studied in a controlled manner,
do not seem to be more effective in treating the PMS than a placebo
(Jordheim, 1972; Reid and Yen
,
1981; Sampson, 1979): Swyer, 1955).
Again, however, uncontrolled studies continue to support the notion
that progesterone treatment can be useful (Berlin, Bergey and Money,
1982; Dalton, 1980; Kerr, Day, Munday
,
Brush, Watson and Taylor, 1980).
It is interesting that several of these authors (Munday, Brush
and Taylor, 1981) later reverse themselves and conclude that it is
unlikely that progesterone plays an important role in the PMS, since
the greatest progesterone deficit occurs at the mid-luteal phase
(days 8 to 9 premenstrually) before symptoms are most severe. They
also feel that the estrogenrprogesterone ratio does not appear to differ
markedly in the PMS , but suggest that there does appear to be a large
difference in estrogen levels at the time of most severe symptoms
(days 1 to 4 premenstrually) . High premenstrual levels of estrogen
have also been cited as a possible factor in the PMS by Backstrom and
Carstensen (1981).
Estrogen is known to affect neurotransmitter concentrations.
High estrogens are usually associated with low norepinephrine
concentrations (La Torre, 1974). It is possible that estrogen
could
affect behavior in different ways depending on the levels
of progesterone
10
present (Munday, Brush and Taylor, 1981). Low levels of estrogen are
known to correlate with high levels of monoamine oxidase which, in
turn, may deplete catecholamines (Abramowitz, Baker and Fleischer,
1982; La Torre, 1974). This evidence, along with research which has
shown that oral contraceptives are associated with increased levels
of premenstrual depression, suggest that estrogens may have a role
in the PMS
,
and one that is more important than the role progesterone
may play (Smith, 1975).
Aside from the effects that estrogen and progesterone may have on
catecholamine levels and subsequent changes in mood, both estrogen
and progesterone are thought to affect changes in fluid retention which
occur premenstrually
.
Estrogen may be involved in premenstrual fluid
retention by increasing synthesis and activity of plasma renin and
angiotensin II. Renin and angiotensin II are known to raise blood
pressure through vasoconstriction. They also increase the output of
aldosterone, a hormone which affects the fluid and electrolyte balance
of the body (Reid and Yen, 1981) . Progesterone may also have a role
in modulating fluid retention and blood pressure, again by affecting
the activity of plasma renin and the secretion of aldosterone. It has
been suggested that in this case, progesterone and not estrogen is
primarily responsible for the rise in renin and aldosterone seen during
the luteal (premenstrual) phase (Reid and Yen, 1981).
11
Aldosterone, Vasopressin and Angiotensin
In normal and PMS women, aldosterone levels are similar. However,
it seems that women with the PMS may excrete larger quantities of
aldosterone than controls. It is possible that increased secretion
of aldosterone might result from stress and/or decreased dopamine
activity levels (Reid and Yen, 1981). But, a recent report by
Munday, Brush and Taylor (1981) found that there were no differences
between PMS women and controls in aldosterone levels. This finding has
been supported by studies which have shown that lowering aldosterone
levels by administering spirolactone (an aldosterone antagonist)
was no more effective than placebo in alleviating premenstrual symptoms
(Smith, 1975).
Like aldosterone, vasopressin, another component of the
renin-angiotensin system which is released by the pituitary, constricts
blood vessels and raises blood pressure. Estrogen may regulate
vasopressin release. Evidence has linked vasopressin to water retention
seen premenstrually and there are some reports, from inadequately
controlled studies, showing the effectiveness of vasopressin antagonists
on PMS symptoms (Reid and Yen, 1981).
Steiner and Carroll (1977) feel that the renin-angiotensin system
is not likely to be involved in the PMS. The fact that aldosterone
activity levels drop six days before menstruation begins, suggests that
it is not likely that aldosterone is related to dysphoria and
water
retention seen in the late luteal phase. This notion is further
substantiated by reports that changes in the renin-angiotensin
system do
12
not occur in anovulatory cycles. Premenstrual depression and
dysphoria, however, do occur in anovulatory cycles, suggesting that
angiotensin is not responsible for mood changes seen premenstrually
(Steiner and Carroll, 1977). It is interesting to note that proges-
terone levels also do not fluctuate in anovulatory cycles, again
suggesting that progesterone does not play a role in premenstrual
dysphoria (Adamopoulos
,
Loraine
,
Lunn, Coppen and Daly, 1972; Steiner
and Carroll, 1977) .
Prolactin
Prolactin has complex influences on gonadal functions and is
responsible for initiating lactation and promoting the growth of
breast tissue. Levels of prolactin (PRL) fluctuate with the menstrual
cycle, having higher levels during the luteal phase than the follicu-
lar, with peak levels occurring at ovulation. It also seems that
PRL levels can vary greatly from woman to woman and from day to day
(Reid and Yen, 1982; Steiner and Carroll, 1977). PRL levels remain
elevated during the late luteal phase, while levels of estrogen and
progesterone are dropping. High levels of PRL are thought to inhibit
ovulation, and at the time of Steiner and Carroll's review (1977),
several authors had found abnormally high levels of PRL in women
with premenstrual tension. More recent studies reviewed by Reid and
Yen (1981) have failed to confirm this finding. Several researchers
have tried to treat the PMS with bromocriptine, a substance which
suppresses the release of PRL by the pituitary, and contradictory results
have been found.
1 !
Rein and Yen argue that although most researchers in this area
assume that PRL is responsible for fluid retention and that it is,
therefore, responsible for premenstrual fluid retention (as well as
perhaps other premenstrual symptoms)
, it has not been established that
PRL has osmoregulatory effects in humans. These authors suggest that
PRL may indirectly affect the PMS by increasing dopamine activity,
which in turn might improve moods or reverse water retention. Reid
and Yen (1981) were, nevertheless, unable to conclude that PRL per se
is an important factor in premenstrual tension.
De La Fuente and Rosenbaum (1981), based on Steiner and Carroll's
1977 review, proposed that excess levels of PRL may interact with
ovarian hormones to produce premenstrual symptoms featured by depression
when estrogen is low, and featured by irritability-hostility when
progesterone levels are low. They support this hypothesis with the
finding that postpartum depression usually occurs at a time when PRL
levels are above normal and estrogen and progesterone levels have
dropped. It seems, though, that these authors did not have access to
the more recent findings reviewed by Reid and Yen which suggest that
PRL is not involved in the PMS.
A more recent study, not mentioned in the review by Reid and Yen,
also supports the view that PRL is not a major factor in the PMS.
Backstrom and Aavaag (1981), in earlier work, had found lowered levels
of progesterone during the luteal phase in women with the PMS. They
had hypothesized that these lowered levels of progesterone might
be
explained by fluctuations in PRL, since this hormone is thought
to influen
14
steroid hormone production and can cause the corpus luteum to produce
insufficient amounts of progesterone. Fifteen women diagnosed
as having the PMS were compared to 17 controls. The mean PRL levels
for the PMS group was not significantly different from that of
controls, even when those women with less severe PMS were excluded
and when possible effects of sampling time were analyzed. Again, it
seems that PRL does not, in itself, play a major role in the PMS.
Endorphins and MSH
Endogenous (within the body) opiate receptors have recently
been discovered and may be involved in many central nervous system
(CNS) disorders. Halbreigh and Endicott (1981) have hypothesized
that decreases in endorphins may be involved in premenstrual depression,
while an increase may contribute to anxious-agitated premenstrual
depression. High levels of endorphins occur during pregnancy and
after birth and, therefore, may be involved in postpartum depression.
Since endorphins, like exogenous (external) opiates have an euphoric
effect, it has been proposed that endorphins may be involved in mania
and depression. Endorphins may also affect dopamine and serotonin
levels associated with depression directly, or indirectly by inhancing
,
dopamine turnover. Drugs such as naloxone and naltrexone, which
block the activity of endorphins, can induce symptoms of increased
sexual desire and dysphoria which are rarely seen together clinically,
but have been reported together premenstrually
.
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Prolactin levels may be higher in women with premenstrual tension
(see above) and since dopamine inhibits the release of prolactin,
elevated prolactin may indicate decreased dopamine activity.
Endorphins may also affect prolactin levels directly, since all
opiates are known to stimulate prolactin.
Opiates interact with norepinephrine, serotonin and acetylcholine,
increasing their synthesis. Serotonin is thought to be related to
changes in depression, irritability, pain sensitivity and sexual desire,
which are changes frequently seen during the premenstrtnr (Halbreich
and Endicott, 1981) .
Reid and Yen (1981) have also hypothesized a role for endorphins
in the PMS and have reviewed other research which may link endorphins
to this syndrome. Endorphins have an antidiuretic effect, increasing
the release of vasopressin (known to regulate fluid retention and modu-
late other pituitary functions) . Endogenous opiates also affect
glucose metabolism (blood sugar levels) by eliciting the release of
glucagon and insulin, resulting in hyperglycemia (high blood sugar)
in humans and secondary hyperinsulism (chronically elevated levels of
insulin) . Disturbances in glucose metabolism have been found
premenstrually
,
particularly hypoglycemic (low blood sugar) conditions,
which could be caused by withdrawal of opiates (Reid and Yen, 1981).
Opiates inhibit appetite and thirst. They may also inhibit the action
of prostaglandin E
x
.
Prostaglandin Ej stimulates fluid secretion in
the small intestines. Inhibition of this action may result in
consti-
pation often associated with opiates. The analgesic effects
of opiates
16
involve cyclic adenosine monophosphate which is stimulated by
prostaglandins. Changes in appetite, pain sensitivity, constipation
and diarrhea are fairly common premenstrual symptoms.
Like Halbreich and Endicott (1981), Reid and Yen (1981) postulate
an abberant release of, or sensitivity to endorphins in the PMS
.
Additionally, they hypothesize that melanocyte-stimulating hormone
(MSH) may also be involved in the PMS. This hormone is known to
increase awareness of environmental stimuli and enhance arousal and
attention. The fact that MSH, like the endorphins, is influenced
by sex hormones and influences pituitary activity makes it a likely
candidate for a role in the PMS as well.
Melanocyte-stimulating hormone (MSH) is a peptide from the
anterior pituitary that influences the deposition of pigment in the
body. Sex hormones appear to have a role in the regulation of synthesis
and release of MSH, estrogen promotes its synthesis, but inhibits its
release, while progesterone enhances release of MSH. In humans,
MSH influences adaptive behavior through its ability to enhance arousal
and attention and to increase awareness of environmental stimuli. Even,
though there is not direct evidence for MSH having a role in the PMS,
the fact that it is known to affect arousal and attention, to stimulate
levels of growth hormone, LH and FSH in humans, and it is known to act
in concert with endorphins, suggests that MSH may modulate mood,
behavior,
and functioning of the pituitary along with endorphins (Reid and
Yep,
1981)
:
17
Endorphin-induced inhibition of central biogenic amine
systems (norepinephrine, serotonin and dopamine) may
produce mood changes, increased appetite and thirst.
Mastodynia (breast swelling), fluid retention, consti-
pation, and abdominal bloating in individual cases
may result from endorphin incited increases in the
levels of prolactin and vasopressin and the inhibitory
effect of endorphins on prolactin action within the
bowel (constipation). Withdrawal of endogenous opiate
stimulus affords relief from these complaints, but may
trigger new symptoms. Increased activity of biogenic
amine systems may produce rapid improvement in mood
and relief from mastodynia, edema and bloating. Release
from opiate inhibition of prostaglandin action may
explain headaches and loose stool which frequently
accompany the onset of menstruation. In exceptional
cases, an excessive rebound to dopaminergic hyperfunction
may explain the development of late premenstrual hyper-
activity, irritability, aggressive and hostile behavior,
or psychosis .. .Differing amounts of gonadal steroid
levels from month to month and from person to person
may account for the heterogeneous and variable clinical
manifestations of this disorder. (Reid and Yen, 1981)
Androgens and Testosterone-Estradiol Binding Globulin
Androgens have been thought to influence sexual desire in women
and both increases and decreases in libido have been noted during
premenstruum. Backstrom and Aavaag (1981) compared the levels of
testosterone and testosterone-estradiol binding globulin (TeBG) in
15 women diagnosed with PMS and 17 normal controls of approximately the
same age. Diagnosis of PMS was determined based on the development of
mental symptoms regularly every premenstrual week, cessation of the
symptoms at the start of menstruation, and no symptoms during the remainder
of the cycle. Mean plasma testogterone levels did not differ significantly
in the PMS group; however, when overall luteal phase concentrations
were
calculated, TeBG binding capacity was higher in the PMS group.
Because
18
active testosterone is thought to be in the unbound form, higher
levels of TeBG binding capacity suggest an overall increase in
bound (inactive) testosterone and a decrease in active (unbound)
testosterone, resulting perhaps in a physiologically less active supply
of testosterone in spite of the fact that mean testosterone concen-
trations did not differ between the two groups of women.
Maureen Dalton (1981) also compared levels of TeBG binding capacity
of 50 women with severe PMS and 50 age-matched controls. She
hypothesized that changes in the binding capacity might be responsible
for changes in total estradiol concentrations which had been previously
reported in the literature. Her PMS group differed, however, from
other studies; all 50 women had suffered severe premenstrual symptoms
leading to mental hospitalization, suicide attempts, criminal
offenses and premenstrual violence. Dalton found that the PMS group
had significantly lower TeBG binding capacity in contrast to the
findings of Backstrom and Aavaag (1981). Like Backstrom and Aavaag,
she also found no differences in total testosterone or estradiol con-
centrations. She hypothesized that perhaps a defect in the liver
might affect production of TeBG. Dalton's findings suggest that higher
levels of active or unbound testosterone and estradiol may exist at the
tissue level. Her findings are more consistent with researchers who
have found high estrogen and low progesterone levels in women with
PMS.
L9
MAO Activity Levels
Another factor which has been implicated in the PMS is monoamine
oxidase (MAO), an enzyme which catalyzes the formation of aldehydes,
ammonia and hydrogen peroxide. Substances which inhibit MAO activity
increase the activity of dopamine, serotonin and norepinephrine in the
brain. Due to this effect on catecholamines, MAO inhibitors are some-
times used as antidepressants (Miller and Keane, 1978). MAO activity
levels may be altered in the PMS. High levels of MAO activity have
been found in premenstrual women and it has been speculated that
progesterone could stimulate MAO activity and be responsible for
the depression seen in some women premenstrually (Abramowitz, Baker
and Fleisher, 1982; Steiner and Carroll, 1977). Some doubt has been
cast on this hypothesis because other authors have found that MAO
activity levels did not correlate with a global scale of menstrual
mood variations (Steiner and Carroll, 1977).
Vitamin A
The use of vitamin A in the treatment of premenstrual pain was
accidentally discovered in 1947 by Simkins, after having administered
the vitamin to treat hyperthyroidism (Block, 1960). Carotene is
thought to inactivate thyroxin and, therefore, reduce thyroid hyper-
activity which often exists premenstrually. It has also been
postulated that vitamin A may inactivate estrogen in the liver and,
in this way, compensate for premenstrual increased estrogen levels.
Block (1960) reported that vitamin A was most useful in reducing
symptoms of headache and tension. Unfortunately, his study
was not
well designed. Two other reports of the effectiveness
of vitamin A
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have been reviewed by Reid and Yen (1981); however, none of these
reports have been substantiated and the topic deserves further
exploration. It is interesting to note that vitamin A intake may
be comprised in a large portion of our population. Lower income groups
of white and black females are more likely to have vitamin A intake
levels below standard. It is extimated that between 18-23% of
these women may be below intake norms (NES
,
1971-72). Data indicate
that vitamin A intake is a major public concern for Spanish-Americans
in low income states (Ten-State Nutrition Survey, 1966-70).
Vitamin B6
Reid and Yen (1981) have done the best review of the theoretical
grounds for the use of vitamin B6 (pyridoxine) in the treatment of
the PMS . Vitamin B therapy has been advocated since the 1940's.
During this period it was thought that vitamin B-complex deficiency
might lead to an excess of estrogen in the PMS. Biskind and Biskind
(1943) had noticed that a vitamin B deficiency in rats impaired
estrogen metabolism, while androgens continue to be inactivated,
leading to an imbalance in the estrogen-androgen equilibrium. They
reported successful treatment of the PMS with vitamin B, as well as
successful treatment of some symptoms of menopause, menorrhagia
(excessive menstruation) , cystic mastitis (breast cysts) , and
metrorrhagia (irregular menses) in women who showed signs of vitamin B
deficiency, glossitis (inflamed tongue) and cheilosis (fissured and
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scaled lips) were the most common of these symptoms. Women were fre-
quently treated initially with parental doses of vitamin B, rather
than oral therapy, as impaired absorption often occurs in nutritional
deficiency. In 1948, during the war, Zondek and Brezezinsky (1948)
studied 14 women who showed severe signs of vitamin B deficiency and
found no signs of impaired estrogen degradation in these women. Their
findings diminished the popularity of vitamin B therapy.
Interst in vitamin B therapy revived when it was discovered that
it acts as a coenzyme (pyridoxal phosphate) in the synthesis of
dopamine and serotonin (Reid and Yen, 1981) . Due to this revived
interest and popularization of vitamin megadoses, cases of vitamin B
toxicity have been reported when taken in amounts ranging from 2 to 5
grams per day (Shcaumburg, Kaplan, Windeback, Vick, and Rasmus, 1983;
Pleasure and Bowen, 1983). Toxic doses of pyridoxine may cause wide-
spread, non-specific axonal degeneration affecting large and small
myelinated fibers and result in impaired sensation, gait and coordi-
nation. These symptoms, in some cases, have only been partially reversible.
An estrogen-induced deficiency of the enzyme pyridoxal phosphate) has
been suggested as a possible factor in depression in women on oral contra-
ceptive and in women with the PMS (Adams, Wynn, Rose, Seed, Folkard and
Strong, 1973; Adams, Wynn, Seed and Folkard, 1974; Herzberg, Draper, John-
son and Nicol, 1971; Rose, 1979). Rose (1978) speculated that estrogen
might alter vitamin B6 distribution and induce enzymes which compete
for
available B6 . Women on oral contraceptives do show a disturbance
of this
itabolic pathway which can be corrected by a pyridoxine
supplement
me I
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(Winston, 1973). Because there are many such enzyme reactions
which are pyridoxine dependent, it has been suggested that a vitamin
B6 deficiency might manifest itself in various ways clinically and
that depression may be only one manifestation of such a deficiency
(Winston, 1973). It is possible that a deficiency of pyridoxine could
contribute to other symptoms seen with oral contraceptives and in the
PMS. Several recent studies have documented an association between
low vitamin B6 serum levels and depression in research comparing
depressed patients with non-depressed patients and controls (Carvey
Williams and Sheffield, 1979; Nobbs, 1974; Russ
,
Hendricks, Chrisley,
Kaliu and Driskell, 1983).
Disturbed glucose levels are observed in women on oral contracep-
tives (Winston, 1973) and have been reported in women premenstrually
.
More recent evidence suggests that carbohydrate tolerance is increased
premenstraully and this might account for cravings often reported by
women at this time (Reid and Yen, 1981). Vitamin B6 supplements have
been shown to improve the impaired glucose tolerance curve seen in
women on oral contraceptives (Winston, 1973) . In a well-controlled
study, vitamin B6 supplements were shown to be effective in reducing
premenstrual levels of depression in women on oral contraceptives
(Adams et al. , 1978)
.
Three controlled studies have been done examining the possibility
that vitamin B6 supplements might alleviate dysphoria associated
th the PMS. In one study (Stokes and Mendels , 1972), 13 women withwi
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PMS, who served as their own controls, were given either placebo or
vitamin B6 supplements in a double-blind manner. These authors found
no differences in moods between the vitamin and the placebo periods
as measured by the Moos menstrual distress questionnaire. The results
of this study are difficult to evaluate, because full details of
the protocol, subjects, and results have never been published.
Supplements were given monthly for an 18-day period prior to and including
the first few days of the menses and dosages were not specified in this
report, but are likely not to have exceeded 50 mg/day. Four women
showed a tendancy toward improvement on the vitamin; however, this
result was not significant. It may be that inadequate dosages were
given or that they were given for too brief a period. It is also
possible that subtle effects due to vitamin supplementation would
not appear with a sample size of only 13. Further methodological
issues will be discussed later in this paper. Mattes and Martin
(1983) used a souble-blind , placebo controlled crossover procedure
to evaluate the fffect of 50 mg of pyridoxine given ten days prior to
menstruation on premenstrual depression in three women. Each
woman reported subjective decreases in premenstrual depression while
on vitamin B6 supplementation vs. placebo condition. Abraham and
Hargrove (1980) used a similar procedure and demonstrated a significant
response of carefully defined symptoms to vitamin B6 in doses of 500 mg
per day compared to placebo. This study, unfortunately, also
used
a small sample size and, therefore, is difficult to
generalize from.
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The fact that vitamin B6 plays a role in the synthesis of dopamine
and serotonin led other researchers to postulate that this vitamin
might alter prolactin levels, since dopamine and serotonin are involved
in the control of prolactin release. Serotonin activity has been shown
to facilitate a rise in prolactin, whereas dopamine inhibits this
release (Mcintosh, 1976). Initial studies showed that vitamin B6
could depress prolactin secretion and, therefore, inhibit lactation
and restore menses in women with amenorrhea (Delitala, Masala, Magna
and Devilla, 1976; Mcintosh, 1976; Reid and Yen, 1981). Several sub-
sequent studies reviewed by Reid and Yen have failed to demonstrate
similar effects. These studies make it seem less likely that
vitamin B6 might affect disorders which result from excess prolactin
levels
.
Again, three studies have assessed the clinical usefulness of
vitamin B6 supplementation for the PMS (Abraham and Hargrove, 1980;
Mattes and Martin, 1983; Stokes and Mendels, 1972). The possibility
that supplementation may be useful needs further substantiation (Reid
and Yen, 1981). This is especially true in light of recent evidence
which suggests that a significant portion of Americans might be
vitamin B deficient. Deficiencies of pyridoxine, thiamin, and ribofla-
vin (B vitamins) often occur hand-in-hand. It is difficult to estimate
their rate of occurrence separately; however, clinical signs of overall
vitamin B deficiency can be observed in a substantial portion of
children and adults (2-18%) in the United States (NES , 1971-72).
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Lithium
Treatment of the PMS with lithium has been explored due to the
cyclic nature of the syndrome and symptoms of depression which commonly
exist. In these ways, the PMS resembled psychiatric disturbances
for which lithium is the treatment of choice (Steiner and Carroll,
1977). Steiner and Carroll (1977) have carefully reviewed the
research in this area and the later review by Reid and Yen (1981) does
not include more recent work regarding the use of lithium to treat
the PMS.
Several researchers in the late 60 's and early 70 's reported a
good effect of lithium in treating the PMS. In 1974, two controlled
studies by Singer, Cheng and Schou (1974) and Mattsson and Von
Schoultz (1974), both double-blind, did not find lithium to be more
effective than placebo in treating the PMS. The women in Singer's
study (n=19) showed equal improvement under both conditions, but
12 of these women also suffered from other psychiatric conditions
throughout the remainder of the cycle which suggests that this sample
did not represent the PMS as it is commonly defined. Mattsson'
s
PMS group did meet the normal criteria: regularly recurring
symptoms which appear 7-8 days prior to the menses and are relieved
by the first or second day of the menses and do not occur at any
point during the remainder of the cycle. This study did, however,
fail to differentiate between subgroups of PMS symptomatology,
i.e., anxiety-tension, depression, irritability, and fluid retention
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(Steiner and Carroll, 1977). Failure to make these distinctions
is common in the PMS literature. More recently, researchers have
been advocating the importance of distinguishing among various
PMS symptom typologies, since it is possible that these subgroups
may be the result of different underlying causes (Halbreich, Endicott
and Schacht, 1982; Haskett
,
Steiner, Osmun and Carroll, 1980; Osborn,
1981; Sampson and Prescott
,
1981; Steiner and Carroll, 1977). In
the Mattsson study, placebo was found to be the most effective
treatment, followed by a diuretic, with lithium the least effective
of the three treatments. Steiner and Carroll (1977) conclude that
the effectiveness of lithium in treating various subtypes of the
PMS is still an open question. It should be kept in mind, however,
that the same criticism (failure to distinguish among symptom
typologies) could be made of most PMS research to date.
The relationship between premenstrual changes and mental disorder
has been explored, but results have been inconsistent (Endicott,
Halbreich, Schacht and Nee, 1981; Halbreich, Endicott and
Schacht, 1982; Haskett, Steiner, Osmun and Carroll, 1980). Again,
the direction of recent work is toward delineating between PMS
and premenstrual worsening of psychiatric disorders. Authors who
have selected women with only PMS have concluded that PMS is not
typically a syndrome of anxiety or depression in the usual diagnostic
sense and that it should not be thought of as a model for recurrent
affective disorders (Haskett, Steiner, Osmun and Carroll, 1980). This
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finding suggests that lithium treatment may not be useful in the PMS
,
since the rationale for the use of lithium was originally based on
the resemblance of the PMS to cyclic affective disorders.
Psychological-Personality Variables
The unusually strong placebo effect seen in most premenstrual
research suggests that psychological and social factors may be
involved in the PMS (Gonzalez, 1981; Jordheim, 1972; Mattsson and von
Schoultz, 1974; Sampson, 1979; Watts, Dennerstein and De La Home, . 1980) ,
The myriad of seemingly unrelated symptoms associated with the PMS
led many to hypothesize that the PMS was a psychosomatic disorder
as early as 1938. Unresolved oedipal conflicts and/or marital conflicts
were postulated as the source of this disorder. Women were thought
to be unconsciously expressing stress or poor attitudes toward
womanhood through their menstrual symptoms (Reid and Yen, 1981).
Authors have reported correlations between premenstrual changes and
disturbed attitudes toward menarche and the menses, guilt around
sexual feelings, severe medical and gynecological histories, poor
marital adjustment, and high neuroticism scores (Reid and Yen, 1981).
Although not of high quality, the psychoanalytic literature
shows a similar picture (Steiner and Carroll, 1977). In one study,
questionnaires were sent to 103 women and it was concluded that, for
these women, menstrual problems were related to traumatic menarche
experiences ( Shainess , 1961). Other analysts have postulated that
the mother-daughter relationship is important in determining future
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attitudes toward menstruation and femininity in general (Deutsch,
1944). Fortin, Wittkower and Kalz (1958), May (1976), and Paulson
(1961) also associated rejection of the feminine role and sexual
guilt with premenstrual symptoms. This view may still be prevalent
today. It would be interesting to conduct a survey of attitudes
toward the PMS among medical and psychiatric professionals.
Premenstrual symptoms have been correlated with various person-
ality factors. Coppen and Kessell (1963) found that neurotic
patients showed the highest premenstrual irritability. Similarly, Watts,
Dinnerstein and De La Home (1980) found that women with the PMS
scored higher on trait anxiety and neuroticism scales, as well as
had more negative attitudes toward their bodies, genitals, sex
and masturbation than controls. In 1975
,
Smith, in his review of
this literature, concluded that the evidence suggested that tense,
anxious individuals, possibly having negative attitudes toward
their sex role, are more likely to complain of premenstrual irrita-
bility, even though nonneurotic women may suffer the same symptoms.
In the case of neurotic individuals, however, it is difficult to
determine which comes first, the cart or the horse, premenstrual
problems or neurotic tendencies.
Somewhat in contrast to Smith's conclusion, Blank, Goldstein
and Chatterjee (1980), in a more recent review of this literature,
concluded that although some evidence suggests that severity of
prementstrual symptoms may in part reflect underlying personality
variables, the bulk of recent literature casts serious doubts on
this
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hypothesis. In particular, these authors cited recent dissertations
by Kleinsasser (1976), DiNardo (1975), and Seagull (1974) which
attempted to correlate neuroticism, sociability, self-sufficiency,
introversion-extroversion, dominance-submission, self-confidence,
locus of control, body attitudes, adequacy of functioning, and
adjustment with premenstrual symptoms. All three authors found that
these measures do not fluctuate with the menstrual cycle or with
severity of the PMS
.
Seagull (1974) concluded that mood and
behavior do fluctuate over the cycle, but that personality factors
do not. Only introversion-extroversion seemed to have any predictive
value, with introverted women tending to rest more, avoid social
contact and report lowered performance efficacy levels during the
menstrual phase of their cycle (Kleinsasser, 1976).
Sociological-Attitudinal Variables
Sociological studies have suggested that social expectations in
many cultures provide women with the opportunity to express stress and
malaise, to regress and to be absent from work around the time of
menstruation. Smith (1975) reviewed the work of authors who suggest
that these social expectations produce a self-fulfilling prophecy
effect for many women. Gough (1975) administered psychological
inventories to 201 young women. He found that the women who reported
the greatest amount of menstrual distress were low on socialization
and high on femininity subscales of the California Personality Inven-
tory. The opposite trend was seen in women who reported the lowest
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amounts of menstrual distress. As mentioned above, Watts, Denner-
stein and Home (1980) found that women with PMS showed more negative
attitudes toward their bodies, genitals, sex and masturbation than
controls. Tarpin (1976) found similar relationships between nega-
tive sexual attitudes and premenstrual distress. May (1976) speculated
that premenstrual tension may be associated with helplessness or
loss of self-control during menstruation in women who he found to be
more assertive, less traditional, and having fewer inhibitions. He
further hypothesized that women who became depressed premenstrually
were expressing another kind of anxiety or the view that menstruation
is an unclean and shameful process. May's hypothesis that helplessness
and loss of self-control may be associated with premenstrual tension
is contradicted by Seagull's (1974) findings that measures of
self-sufficiency and locus of control do not vary over the menstrual
cycle
.
Based alone on the high placebo response rate seen in premenstrual
research, it seems fair to assume that personality and social-attitudi-
nal factors play a role in the development and expression of
premenstrual symptoms. It is also likely, however, based on the
physiological literature, that somatic factors play as large, if not
larger, role in influencing the PMS (Parker, 1960; Reid and Yen,
1981; Smith, 1975; Steiner and Carroll, 1977). It seems clear that
psychological and physiological interactions are inseparable and
circular in their ability to influence each other. It is probably
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futile to attempt to rate either factor as more or less important.
The most useful model seems to be one that conceptualizes a
complex, and perhaps circular, pattern of interaction and feedback
between psychological-social and physiological variables.
Performance
Feminists have long argued that fluctuations in the menstrual
cycle and concommitant fluctuations in hormonal levels ("raging
hormones") do not render women incompetent or unreliable in terms
of performance on the job or elsewhere. In fact, this arguement is
well supported by the literature (Blank, Goldstein and Chatterjee,
1980) .
An exception is some work of Dalton's, reviewed by Tasto and
Insel (1977), which suggests that lowered performance may occur
in adolescent women during menstruation. She studied school girls
in an English boarding school and found that forgetfulness increased
menstrually in the girls who were more intelligent and free of
psychological stress. She has also found lowered examination
performance in similar studies. It is not clear how well conducted
these projects were.
Blank, Goldstein and Chatterjee (1980) have reviewed the perfor-
mance literature more extensively. Mild decreases in performance
were found premenstrually and menstrually in a study by Stocker
(1974). Contrary to these findings, is the work of Berstein (1977)
who found no differences between premenstrual/menstrual and inter-
menstrual academic performance in a sample of college women. Both
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Golub (1974) and Summer (1972) found no differences in intellectual
test scores over the menstrual cycle, although Golub's subjects
made subjective reports and had expectations to the contrary. (It
is interesting to speculate about the meaning of these negative
expectations.) Zimmerman and Parlee (1973) also support these
findings. Basic sensory-motor processes
, such as reaction time
and concentration time showed no changes. This trend also seems
to be true for speech fluency (Silverman and Zimmer, 1976).
In spite of Dalton and Stocker's findings, the literature
fairly consistently challenges the social stereotype that women are
not as competent during the premenstrual and menstrual phases of
the cycle. But for women who suffer from severe PMS , this may
not be the case.
Research Objectives
Although it seems logical that some form of dietary supplementa-
tion might ameliorate premenstrual symptoms (indeed, vitamin therapy
has dramatically increased in popularity among lay people in recent
years)
,
very little controlled research has been done to test the
effectiveness of nutritional supplementation in treating the PMS.
Renewed interest in vitamin B6 therapy occurred with the
discovery that this vitamin acts as a coenzyme in the biosynthesis
of the neurotransmitters dopamine and serotonin. Both of these
neurotransmitters have been implicated in a variety of disorders
of mood and behavior (Reid and Yen, 1981). Vitamin B6 is
involved
33
in many other metabolic activities, including protein synthesis,
converting glycogen to glucose to provide energy for muscle tissue,
the production of red blood cells, proper functioning of nervous
tissue, and the metabolism of certain fatty acids (Robertson,
Flinders and Godfrey, 1976). In view of the many decarboxylase
and transaminase reactions that are vitamin B6 dependent, it is
likely that a functional deficiency of pyridoxine would manifest
itself in several ways clinically, and not only as depression
(Winston, 1973). This potential for multiple manifestations is
attractive in relationship to the PMS, given the variety of symptoms
that can be associated with this syndrome.
Along with dopamine and serotonin synthesis, vitamin B6 has
been linked to improper glucose metabolism (Winston, 1973), estrogen
metabolism (Biskind and Biskind, 1943), prolactin levels (Mcintosh,
1976), and premenstrual depression in women on oral contraceptives
(Adams e_t al_.
,
1973) . Many normal American diets may be marginal in
vitamin B6 content, since 75% of this vitamin is removed by food
processing such as milling and heat (Robertson et al_. , 1976). It has
recently been estimated that 2-18% of the population may be vitamin
B deficient (NES, 1971-72).
The possibility that pyridoxine may be useful in treating the PMS
still needs further substantiation (Reid and Yen, 1981). Given the facts
mentioned above, it is likely that nutritional supplementation of
pyridoxine might have beneficial effects on premenstrual symptoms
and in particular, premenstrual depression.
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The present research effort was designed to examine the effects
of vitamin B6 supplementation on the premenstrual syndrome. If
vitamin B6
,
in fact, has beneficial effects on physiological
functioning, these beneficial effects should eventually act to
decrease premenstrual dysphoria, and perhaps other symptoms as well.
One would expect to see a decrease in reported depression, irrita-
bility, tension, and anxiety during the premenstruum
. This
research was specifically designed to assess the hypothesis that
vitamin B6 may exert beneficial effects over time on levels of
depression and anxiety.
Preliminary Research Findings
To examine the effectiveness of pyridoxine supplementation on
premenstrual symptoms, a pilot study was designed using a double-blind
crossover procedure. Advertisements were placed in local newspapers
asking for volunteers. These women were screened based on the follow-
ing selection criteria: women could not be taking any oral contra-
ceptives, be on any regular medication or in poor health. They
had to be between the ages of 20 and 40 and have fairly regular
menstrual cycles. Volunteers were told that they would receive
a token sum if they completed at least four months of the study and
an additional sum if they completed the entire six months of the study,
Approximately 80 telephone responses were screened and 40 of these
callers were recruited for an initial interview and data collection.
Of the 30 subjects who agreed to begin the home record keeping, a
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final sample of 9 subjects completed six months of a parallel study
examining the effects of dietary sodium intake, and only 4 subjects
completed six months of the pyridoxine pilot study.
Baseline data were collected over the first two months of
the project. During this time, a routine of home record keeping
and three monthly office visits was established. Subjects were
asked to fill out 12 questionnaire packets per month. These 12
packets were filled out starting on day one of the cycle, for the
first three days of menstruation. The second group of packets was
filled out for three days during the follicular phase and prior to
ovulation. (Interviewers carefully worked out individual schedules
with each woman according to the expected length of her cycle.) The
third set of questionnaires was filled out for three days during the
luteal phase (about 10 days prior to menstruation) , and the final
set was filled out as nearly as possible to the last three days
before the onset of the next cycle. The rationale for this approach
was based on the need to gather data from different phases of the
cycle, yet minimize the time and effort that would be demanded from
volunteers. It was found, however, that even for subjects who
reportedly had regular cycles, there was enough variation in their
cycle length to make it difficult to accurately calculate the phases,
so that in a number of instances women started their next cycle while
filling out the premenstrual packet, or conversely, ended up not
starting the next cycle for a considerable time following what was
to have been the premenstrual set of questionnaires. This problem
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will be addressed in the research described here. In addition to
home records, subjects were asked to come into the research office
three times per cycle to deliver their completed questionnaires and
to have their weight and blood pressure checked.
After baseline data were gathered for two complete cycles, the
experimental procedure was begun. Each of the 4 subjects
was randomly assigned to take either the placebo or the vitamin B6
supplement, 3 times per day, one tablet with each meal, totalling
150 mg/day. No other dietary changes or manipulations were made.
After a two month period the crossover was begun and the groups
were reversed. Interviewers who met with subjects and supplied
them with the tablets were blind to the condition of the subject.
Home record keeping included the short form of the Zuckerman
and Lubin (1965) Multiple Affect Adjective Check List, which has
scales measuring levels of depression, anxiety and hostility. It
also included the Moos Menstrual Distress Questionnaire (MDQ)
,
which has a number of scales reflecting a variety of affective,
behavioral, and physical menstrual cycle symptoms (Moos, 1968). In
addition to these standard instruments, the packets included food
frequency check lists with a representative assortment of common
foods which were scored for rough indications of sodium intake, sugar
intake, and total intake, as well as B6 and potassium intake. Finally
the packet contained a brief questionnaire asking subjects to assess
their appetite, activity level, number of experienced stressors,
and
food cravings.
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Thirty-six subjects completed the baseline period of two
months. Average scores for the four phases of the cycle were
calculated using these subjects' data. These averages revealed a
U-shaped pattern if plotted over the month. Increasing levels of
negative affect were seen menstrually, followed by lower levels
during the mid-cycle phases (follicular and luteal), with a gradual
increase in negative affect occurring again during the premenstrual
phase of each cycle. This U-shaped pattern was seen in all of the
measures of dysphoric mood. As might be expected, arousal (positive
affect) showed the opposite pattern, increasing in the mid-cycle
phases and decreasing in the menstrual and premenstrual phases.
In order to examine the data for overall changes in moods
between the baseline, treatment and placebo phases of the study,
an average over all phases of the cycle was calculated. When
these overall baseline, placebo, and treatment phase means were
calculated on the 4 subjects in the B6 study, all mood measures
except hostility and arousal were lowered under both the placebo
and the treatment conditions. Both the Moos and the MAACL measures
of anxiety and depression showed this trend, and it was also seen
in the Moos measure of amount of mood swing. The additional decline
associated with vitamin B6 supplementation, beyond that consistently
seen under the placebo condition, was usually small. The largest
increased effects of B6 were seen in the Moos measures of depression
and mood swing, although placebo effects followed closely behind.
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Treatment with B6 was consistently more effective than treatment with
placebo alone. But these differences were small.
When similar comparisons were made looking at water retention and
menstrual pain, treatment with vitamin B6 made a greater improve-
ment than placebo. As might be expected, declines during the menstrual
and the premenstrual phases of the cycle accounted for the largest
portion of the overall decline in the pain and water retention
measures. Hostility and arousal (positive affects) do not seem to
have been affected by B6 supplementation.
With a sample size of 4, these results are very likely to reflect
chance variation. But declines in levels of depression, anxiety,
mood swing, water retention, and menstrual pain suggested that
further research was needed to examine the possibility that B6
supplementation might be significantly more beneficial than treatment
with placebo in ameliorating the negative affect experienced
premenstrually and menstrually.
Discussion of Methodology
The pilot study was handicapped due to small sample size and
large amounts of variability in measurements, making it difficult to
detect what are perhaps subtle effects on mood levels resulting
from changes in dietary intake. Variability was introduced by
inaccurate calculation of menstrual cycle phase, seasonal changes,
random life events affecting within subject variability, age
differences, and perhaps differential responses from a variety of
premenstrual subtypes. The most serious problem overall seemed
to be
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the extreme variability of subject responses from cycle to cycle.
As might be expected, moods and food intake are highly responsive to
external stimuli as well as to menstrual cycle phases. Seasonal
influences — including holidays, weather, and semester endings for
students — can mask more subtle cyclic effects. Using more subjects
or investigating individual patterns more carefully by using a
longer time period are possible approaches to this problem.
The willingness of subjects to keep records was encouraging.
In follow-up interviews, subjects tended to object to the record
keeping the least, and to the office visits the most, suggesting
that future increases in the amount of home record keeping demands
would be feasible. Matching subjects for age and symptom typology
would lessen between-subject variability. Recruiting several
separate groups of volunteers, each overlapping one month in their
participation, would control for some variation due to seasonal
changes and academic schedules. It was also found to be important not
to rely on retrospective reports on menstrual symptom severity, since
this pilor revealed an interesting discrepancy between retrospective
reports of symptoms and daily reports of symptoms.
Before formally introducing the methods adopted for this research,
it would be useful to summarize comments other researchers in this
field have made regarding methodology in addition to the considera-
tions mentioned above.
Defining severity and subclassifying premenstrual changes
recently have become more important factors in PMS research.
The etiology of the PMS still remains obscure and the major reason
for this obscruity may be the wide variation in definition found
in this field. The importance of descriptive clarity, reliability
of measurement and classification has been highlighted in recent
articles (Halbreich, Endicott
, Schacht and Nee
, 1982; Steiner,
Haskett and Carroll, 1980).
Most researchers have used a single definition of premenstrual
syndrome that combines different dimensions of change or symptoms
that might be seen premenstrually (Halbreich et^ al_.
,
1982) . Moos
(1969) has attempted to delineate dimensions of premenstrual change
to some extent by factor analyzing common symptomatology (47 items)
into 8 symptom clusters: pain, water retention, concentration,
behavioral change, autonomic reactions, negative affect, arousal, ar
a control scale. These scales also allow for some assessment of
severity. More recently, Steiner, Haskett and Carroll (1980) have
attempted to develop more specific criteria for the premenstrual
syndrome. They have developed two scales for rating the severity
of premenstrual symptoms based on a study of women with severe
premenstrual symptoms and no evidnece of symptoms at other phases oJ
their menstrual cycle, and who had reported premenstrual dysphoria
for at least six consecutive cycles. From this data and previous
research, these authors established a research diagnostic criteria
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for a single premenstrual tension syndrome.
Based on the work of Moos and the authors above, a new assess-
ment, the Premenstrual Assessment Form (PAF) has been developed which
attempts to further delineate subtypes of mood, behavior and physical
changes be defining inclusion and exclusion criteria with cut-off
points to aid in differentiation (Halbreich, Endicott and Schacht, 1982;
Halbreich, Endicott, Schacht and Nee, 1982). The diagnostic criteria
developed by Steiner, Haskett and Carroll (1980) was used in this
research to verify that subjects did, in fact, suffer from the PMS
.
The PAF was used to further differentiate between symptom typologies
when possible.
Consistent with the findings of the pilot study are reports by
other researchers that retrospective ratings are frequently discrepant
from data obtained daily throughout the menstrual cycle. It has
been suggested that the mood of a subject on the date which the
rating is undertaken may be responsible for this discrepancy
(May, 1976; Sampson and Prescott , 1981). Assessing premenstrual
symptoms at a predetermined time can be difficult, since the menstrual
cycle is generally somewhat unpredictable from month to month (Sampson
and Prescott, 1981). This problem was of major significance in our
pilot study. Also, if there is no record of a subject's scores during
non-premenstrual phases, there is no way to assess symptom patterns.
Daily or every-other-day recording of symptoms appears to be the most
reliable method of assessing symptom patterns and degree of severity
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(Rossi and Rossi, 1980; Sampson and Prescott
,
1981). It is still
possible that social stereotypes might influence how subjects rate
their moods and symptoms; however, with a controlled experimental
design and large enough sample sizes, treatment effects should
still appear if they exist.
Sampson and Prescott (1981) recommend self-ratings of moods and
physical symptoms over observed behavior or rater assessments.
In assessing treatment, observable behavioral events are normally
going to be too few in number to indicate response to therapy and
there is no agreement about whether measures such as the galvanic
skin response and reaction time are related to symptom severity.
Rater assessments are usually weakly correlated with self-ratings
when based on projective tests and interviews suffer from the same
drawbacks as retrospective ratings.
Among the self-rating methods which are available and commonly
used are individual checklists using a 3-4 point scale or a
10 cm line scale, more general anxiety and depression scales (Beck
depression scale, Zuckerman and Lubin check list), or the Moos
Menstrual Distress Questionnaire (MDS) , which is specifically
designed to assess menstrual cycle symptomatology. The MDQ appears
to be the most widely used self -rating scale in PMS research
(Sampson and Prescott, 1981).
Statistical problems can result in assessing whether a treatment
is better than a placebo when there is a high placebo response, as
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in the case of PMS
.
It is, therefore, necessary to have an untreated
cycle before assessing treatment response and to ensure that a
subject actually does fit the diagnostic criteria for PMS. This
research project has been designed with these considerations in mind.
CHAPTER II
METHOD
Setting
This study was primarily conducted in the home environment.
Subjects were asked to keep daily records of their moods and menstrual
cycle symptoms. These records were filled out by each subject in
the evening to insure, as much as possible, that similar conditions
prevailed when ratings of moods and other symptoms were recorded.
One monthly visit to the research office was required. The
visits were scheduled according to individual cycles so that they
occurred during the mid-cycle phase. Follow-up interviews with
participants from the pilot study indicated that subjects were most
reluctant to make office visits and least reluctant to keep home
records. It was hypothesized that subjects would be more willing to
make office visits when they occurred during the mid-cycle phase,
rather than during perhaps more difficult menstrual and premenstrual
phases of the cycle. The number of appointments were reduced from
3 to 1 /month, and record keeping was increased from a total of 12
days /month (divided into four 3-day segments) to daily record keeping.
Length of participation was reduced from six months to three months
in duration. The goal of these modifications was to maximize the numb
of participants by minimizing the time commitment, but intensifying
record keeping demands.
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Subjects
Fifty-five women participated as subjects. Subjects were recruited
on a voluntary basis and received $12.00 upon completion of the study.
Advertisements were placed in local newspapers and university
bulletins. Approximately 110 telephone responses were screened and
83 of these callers were recruited for an initial interview.
Initial in-person research office appointments were scheduled for
women who met the following criteria: Absence of oral contraceptives
and an I.U.D.; lack of regular medications and any serious medical
problems; women had to be planning to stay in the area and not be
planning a pregnancy; women could not be taking more than a common
daily vitamin supplement; and they must have reported regular recurring
premenstrual mood changes that were moderate to severe in nature and
noticeable to friends or relatives. Women also had to have a
fairly regular menstrual cycle. Women who reported that they occasion-
ally skipped cycles were not allowed to participate. The mean age
of the participants was 28, and ages ranged between 17 and 41.
Initial interviews involved further description of symptoms
and their timing. These interviews provided an in-depth description
of the study to volunteers and details about home record keeping were
provided. Women were then asked if they were willing to participate
for three monthly cycles. These interviews were conducted by trained
undergraduate research assistants.
Of the 74 subjects who agreed to begin the home record keeping,
a final sample of 55 subjects completed three months of the study.
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This tally represents a 26% dropout rate and is a marked improvement
over the 57% dropout rate seen in our pilot study. This improvement
suggests that minimizing time commitment and intensifying record
keeping did act to maximize the number of participants.
Research Design
A placebo controlled, double-blind procedure was used. In order
to avoid crossover effects, as well as minimize time commitment on
the part of volunteers, this project did not use a crossover design
balanced for crossover effects as was used in the pilot study. Because
it was hypothesized that seasonal influences — holidays, weather,
and semester endings for students — might mask more subtle cycle
effects on mood, three separate groups of subjects were run (Gi
,
Gil,
GUI), each for a three-month period, at three times of the year, such
that each group overlapped in duration with the previous group in an
attempt to balance for seasonal effects. Figure 1 illustrates when each
group of subjects began in the study, the range of duration of their
participation, and where they overlapped in time. Holidays and exams,
which are thought to be particularly stressful times of the year,
are noted in the figure.
All subjects were asked to describe their menstrual cycle symptoms
in detail and were asked to describe an average day's food intake.
All women were asked to keep baseline home records for a period
of one menstrual cycle, beginning on day number one of their next
cycle. Volunteers were then asked to take a vitamin B6 supplement or
a placebo three times per day, or once with each meal, totalling 150 mg/day
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FIGURE 1. Range of duration and overlap of Groups I, II,
and III across seasons with holiday, exam, and
tylenol scare periods highlighted. In Group I,
50% of the subjects were in the third month of
the study during the stressful winter exam and
holiday season. In Group II, 59% of the sub-
jects were in the first month, or baseline
phase of the study during the holiday season.
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for those on the vitamin B6 supplement. Subjects in Group I received
a matching small white tablet form of placebo and vitamin B6
.
Subjects in Group II and Group III received placebo and vitamin B6 in
matching brown gelatin capsules. This aspect of the study was not
planned. The serendipity of this procedure led to seeing differential
placebo effects, as will be discussed in the results section.
Subjects were blind to the treatment, as were their interviewers.
In order to assure uniformity of groups, subjects were matched for age
and premenstrual symptomatology as closely as possible and then randomly
assigned to receive either the vitamin or placebo. Interviewers were
balanced across subjects for age and condition. No significant differ-
ences in baseline scores were seen between any of the three groups (Table 1)
and demographic characteristics matched as well (see Table 2 )
.
Volunteers continued their home record keeping for two cycles while on
the placebo or vitamin supplement. At the end of the entire three
month period, subjects were told which condition they were under,
received payment, and a full description of the study, including a
description of their own menstrual cycle variations in mood and other
symptoms
.
Procedures and Measures
The constructs of interest in this study were mood and physical
symptoms. A pretest measure of general menstrual cycle symptoms was
given to each subject at the intial interview in order to differentiate
between those who fit diagostic criteria for PMS (Steiner, Haskett and
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Table 1
Summary of Paired t-Test Comparisons on Baseline
Levels between Groups I, II, and III
(none significant)
Anxiety-Semantic Differential («* =
.005):
.Group I Group II Group III F-ratio d.f
Cycle Average
f!" 5 ' 185 5 -^9 4.983 0.840 53S - D
- 1.361 0.879 1.426
Premenstrual Phase
Ave
- 6.118 6.052 5.726
S
-
D
- 1.730 0.994 2.352
2
« Depression-Semantic Differential (*=.005):
0.255 53
Cycle Average
Ave
- 4.880 5.285 4.803 1.150
S-D. 1.233 0.780 1.221
53
Premenstrual Phase
Ave. 5.655 5.639 5.610 0.004 53
S.D. 1.582 1.030 1.966
3. All Negative Affect-Semantic Differential (<*=.005):
Cycle Average
Ave. 5.097 5.545 5.111 1.080 53
S.D. 1.240 0.761 1.306
Premenstrual Phase
Ave. 5.941 6.020 5.816 0.083 53
S.D. 1.600 0.914 2.053
4. Perceived Stress Level-Semantic Differential (^=.005):
Cycle Average
Ave. 5.114 4.884 4.659 0.666 53
S.D. 1.345 1.018 1.082
Premenstrual Phase
Ave. 5.249 4.540 4.997 0.841 53
S.D. 1.842 1.469 2.010
51
Table 1 (continued)
Group I Group II Group III F-ratio d.f.
0.397 53
0.438 53
5. Menstrual Pain-MDQ-T (* =.005)
Cycle Average
Ave. 2.245 2.108 2.123
S ' D
- 0.477 0.391 0.680
Premenstrual Phase
Ave
- 2.278 2.409 2.510
S - D
- 0.647 0.701 0.844
6. Poor Concent rat ion-MDQ-T (<*=.005):
Cycle Average
Ave
- 1.747 1.650 1.576 0.521 53
S.D. 0.467 0.461 .0552
Premenstrual Phase
Ave
- 1.963 1.841 1.906 0.141 53
S.D. 0.731 0.585 0.880
7. Behavior Changes-MDQ-T (c*=.0Q5):
Cycle Average
Ave. 1.717 1.571 1.513 0.929 53
S.D. 0.501 0.320 0.552
Premenstrual Phase
Ave. 1.796 1.682 1.677 0.194 53
S.D. 0.658 0.547 0.776
8. Autonomic Symptoms-MDQ-T (<* = .005):
Cycle Average
Ave. 1.320 1.344 1.374 0.078 53
S.D. 0.394 0.374 0.445
Premenstrual Phase
Ave
.
S.D.
1.500 1.545
0.454 0.722
1.531
0.591
0.028 53
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Table 1 (continued)
Group I Group II Group III F-ratio d.f
9. Water Retention-MDQ-T (£*'=. 005)
Cycle Phase
Ave
- 2.187 2.237 2.218
S
-
D
- 0.368 0.476 0.747
Premenstrual Phase
Ave
- 3.056 3.318 3.177
S - D
- 0.802 1.041 0.995
10. Negative Af fect-MDQ-T (c*=.005):
0.042 53
0.376 53
Cycle Phase
Ave
- 2.354 2.328 2.225 0.189
S-D. 0.693 0.594 0.662
53
Premenstrual Phase
Ave. 2.583 2.591 2.604 0.003 53
S.D. 0.845 0.766 0.935
11. Positive Af fect-MDQ-T («*=.005):
Cycle Phase
Ave. 2.501 2.349 1.978 2.752 53
S.D. 0.653 0.650 0.699
Premenstrual Phase
Ave. 2.343 2.227 1.719 3.137 53
S.D. 0.942 0.703 0.632
12. Lack of Control-MDQ-T (#=.005):
Cycle Phase
Ave. 1.297 1.183 1.189 0.615 53
S.D. 0.495 0.267 0.240
Premenstrual Phase
Ave. 1.380
S.D. 0.832
1.250
0.370
1.313
0.544
0.231 53
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Carroll, 1980) and to further differentiate between premenstrual
symptom typology (see Appendix A)
.
Initial assessment included the Premenstrual Assessment Form (PAF)
developed by Halbreich et al
.
(1981). The PAF asks a woman to rate her
last three cycles overall, to rage only the premenstrual phase of those
cycles, and to rate the degree of symptom change from normal levels.
The PAF contains 94 items which enable it to make fine distinctions
between symptoms. This form was used for initial assessment, subtyping
and for matching subjects in this study.
An initial interview designed for the purposes of this study was
also administered. This interview was conducted by research assistants
and asked that each woman describe a typical day's food intake, the
onset, duration, severity and type of menstrual symptoms they regularly
experienced. They were asked if these symptoms peaked at any point,
and when symptoms ended (see Appendix A)
.
During the three months of the study, each woman rated her mood
on a daily basis and her menstrual symptoms every other day. The Moos
Menstrual Distress Questionnaire, form T (Moos, 1969) was used to
measure change in menstrual symptoms. It allows a women to describe th
menstrual symptoms she experiences on a daily basis. A list of 47
symptoms commonly experienced menstrually and premenstrually are each
rated in severity on a 1-6 scale. This scale provides a measure of
absoluate degree of symptoms in contrast to the PAF, which attempts
to measure degree of symptom change from normal baseline levels. The
MDQ-T items have been factor analyzed and fall into eight symptom
subgroups: pain, water retention, concentration, behavior change,
negative affect, arousal (positive affect), autonomic reactions, and
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control. The symptom subgroups of major interest in this study were
negative affect, arousal, pain, and water retention. The pain scale
reflects symptoms usually associated with dysmenorrhea, whereas the
negative affect scale reflects symptoms generally associated with the
PMS (see Appendix A)
.
A semantic differential form designed to rate levels of anxiety,
depression and stress was administered daily to each woman. This
checklist contains ten items selected to reflect depressive moods,
five items to reflect anxiety, and one item which rated how stressful
the day was perceived to have been. Adjectives which are polar oppo-
sites of each other were separated by a 10cm line (Osgood, Suci
,
Tannenbaum, 1957) . Women were asked to indicate how they felt on that
day by marking along the line in the place that best described their mood
for the day. Adjectives reflecting depressive mood were selected from
the Zung Self-Rating Depression Scale (Zung, 1965) and the Radloff
Depression Scale (Radloff, 1977). Items reflecting anxiety were
selected from the State-Trait Anxiety Inventory (STAI, Form XI)
designed by Speilberger, Gorsuch and Lushane (1968). To avoid a halo
affect in the daily mood measure, five separate alternating forms were
used, each containing the same items, but counterbalanced and scrambled
in order. Subjects were told that each form was not identical to the other
and that care should be taken in filling them out. (see Appendix A).
Women were asked to return all unused pills at the end of each
month's cycle, so that compliance could be assesses by pill counts.
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Postcards were mailed to remind subjects to return forms by mail on a
bi-weekly basis, and telephone reminders were made before each
scheduled office appointment. Exact rate of compliance could not be
obtained, since pill counts were not completed on every subject.
Estimates of compliance were based on completed pill counts only.
These estimates are fairly consistent across groups (Group I = 86.8%;
Group II = 87.5%; and Group III = 74.5%) with Group III appearing to
be the least compliant.
Women were asked to fill out a post-study questionnaire and received
a follow-up letter (see Appendix B)
.
CHAPTER III
RESULTS
Many authors assess the significance of changes in systems by
subdividing the menstrual cycle into phases and adding symptom scores
for each phase together. Comparisons are then made between scores
(Sampson and Prescott, 1981). Phase definition, however, differs often
from study to study, varying in number from four to seven. Rossi and
Rossi (1980), after an extensive review of the literature and an analysis
of their own preliminary data, chose to divide a cycle into five phases.
They assumed a 28-day cycle and made appropriate adjustments for data
analysis when cycles exceeded or did not reach this standard length.
The criteria for phase definition, as outlined by Rossi and Rossi,
includes every day of the menstrual cycle, and separates these days
into a menstrual, follicular, ovulatory, luteal, and premenstrual
phases. These divisions resulted from their findings that mood patterns
unique to the luteal phase existed and that premenstrual and menstrual
phase mood profiles were less consistent than expected. Their protocol
for phase definition was used to analyze data generated from this study.
Group Equivalence
In order to assess whether there were any significant differences
between Groups I, II, and III at baseline, paired t-test comparisons
were made on each construct of interest. These constructs included a
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semantic differential measure of Anxiety, Depression, overall Negative
Affect, and Perceived Stress, as well as MDO-T measures of Menstrual Pain,
Poor Concentration, Behavior Change, Autonomic Symptoms, Water Retention,
Negative Affect, Positive Affect, and Perceived Lack of Control. No
significant differences in these measures were found at baseline
between Groups I, II, and III (£ee Table 1). Comparison of demo-
graphic variables between groups did not show marked differences (see
Table 2 ) , nor were there marked differences in compliance rates
between groups as noted in the Method section. These data indicate
that Groups I
,
II
,
and III were equivalent in composition, compliance,
and in degree and duration of premenstrual symptoms.
Effect of Vitamin B6
In order to assess the effectiveness of vitamin B6 on ameliorating
premenstrual symptoms, an analysis was conducted on each individual
group. In Group I, there was a significant effect of vitamin B6 on Poor
Concentration during the premenstrual phase of cycle three (F=19.90;
p < .005) . In Group I, effects which approached significance were seen
premenstrually in cycle number three in Negative Affect (F=14.40;
p < .01) , Behavior Change (F=13.40; p < .01) , and Autonomic Symptoms
(F=11.27; p <.01). In Group II, there was a significant effect of
B6 on Poor Concentration during the follicular phase of cycle number
two (F=41.65; p < .001). A covariance analysis adjusting for baseline
values was conducted using a significance level of p< .005 (F^ ,8=14.69)
in order to control for variations that might exist across groups in
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baseline levels of menstrual symptoms. When data from Groups I, II,
and III were combined (n=56)
,
there were no significant effects
revealed by the analysis of covariance
.
Three significant results (p < .005) and three results nearing
signifiance (p < .01) were obtained out of 72 tests (2 cycles x 3 groups x
12 measures). At the p < .01 level, one would expect .7 significant
results by chance and .35 significant results by chance at the p < .005
level; therefore, it is unlikely that the six results mentioned above
were obtained by chance. Four of the six results were seen in the
premenstrual phase of cycle number three in Group I. In three of
these four cases, the vitamin B6 condition remained constant in measures
across time. In all four cases, the placebo condition scores increased
(or worsened) in value over time. It is also interesting to note that
in three out of the six findings, the measure which was affected was
Poor Concentration as measured by the MOOS menstrual distress
questionnaire. The size of the effects in Group I were relatively large.
Based on a six-point scale, the mean level of Behavior Change noted in
Group I during the premenstrual phase of cycle three was 2.7 in the
placebo versus 1.4 in the B6 condition. Similar size differences were
seen for Autonomic Symptoms ( xplacebo
= 1,8 versus X^ = 1-1); Negative
Affect (X
, ,
3.3 versus X„, = 2.4); and Poor Concentration
placebo do
(X =2.7 versus X^ = 1.5) in Group I. These findings are summar-placebo Bo
ized in Table 3 and Figure 2 . Figure 2 suggests that vitamin B6 was
more effective in improving Poor Concentration, Autonomic Symptoms, Water
Retention, Perceived Stress Levels, Behavior Change, and in increasing
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Paired t-tests which were significant or approached
significance in Group I. This figure illustrates
that the effect of vitamin B6 in Group I was to
hold premenstrual symptoms at an even level while
symptoms worsened under the placebo condition. It
also illustrates that this effect occurred in the
third month.
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Positive Affect than the placebo in Group I when Mean Change Scores
are compared. Mean Change Scores baseline
-(Mo 2 + Mo 3) /2 J
illustrate the direction and size of change in scores between the base-
line and treatment phases of the study. A pattern for direction
and size of. change in symptoms can be discerned from a visual
inspection of Mean Change Scores. Again, in this case, Mean Change Scores
show that B6 was more effective than placebo as a treatment in Group I.
Figure 2 illustrates that the effect of B6 on Poor Concentration during
the premenstrual phase of cycle three in Group I is the result of placebo
scores having increased dramatically, while B6 scores remained fairly
constant during the third cycle. This trend suggests that B6 perhaps
played a "protective role" by preventing a rise in Poor Concentration
which otherwise might have occurred. Cycle three of Group I corresponded
with a potentially stressful time of the year for both female students and
employed women, winter finals and holiday season (see Figure 1). In
Group I, 50% of the subjects were in cycle three of the study during winter
exams and holiday season. Subjects reported a higher Perceived Stress
Level during this period when scores were compared to theoretically
less stressful periods of time. In Group I, the mean Perceived Stress
Level score for the period between 12/15/82-12/26/82 was 5.47 as compared
to 4.89 for the period between 11/30-12/15 (an 0.6 point difference on a
1-10 point scale). In Group II, the mean Perceived Stress Level score
for the period between 12/15-12/26 was 5.35 as compared to 4.5 for
the period between 1/15/83-1/26/83 (an 0.85 point difference on a 1-10
point scale) . These averages are consistent with the suggestion that
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FIGURE 3. *Mean change scores between baseline and treatment phase
of the B6 condition in Group I and placebo conditions
of Groups II and III (Premenstrual Phase) . This figure
illustrates that the placebo in Groups II and III had
a larger effect on premenstrual symptoms than vitamin
B6 had on premenstrual symptoms in Group I subjects.
X = Baseline - £(Month 2 + Month 3) f 2J
change
*A change in the negative direction indicates improvement
in intensity of premenstrual symptoms in all measures
except positive affect.
pmm
o o
M
U C
<TJ O
i-J CJ
o <
&4
2 <
XS5333
> oo
fa eA nj
oq O
a
O U
o a
cu oU
< ao
01
z
66
subjects in both Groups I and II perceived themselves to be under more
stress during the winter exam and holiday season than other periods
of the year.
Effect of Placebo
Paired t-test comparisons were made to determine whether there were
significant differences between Group I, II and III in the effectiveness
of the placebo. This was an important question, particularly because the
perceptual characteristics of the placebo (and vitamin) varied between
Groups I, and Groups II and III. Group I received the placebo and vita-
min in matching tablet form. Groups II and III received placebo and
vitamin in matching capsule form. Paired t-tests revealed no signifi-
cant differences in the effect of placebo among Groups I, II and III.
Nevertheless, the placebo effect in Groups II and III is greater than
the effect of vitamin B6 in Group I on lessening the intensity of
premenstrual symptoms in 10 out of 12 measures when Mean Change Scores are
compared (p = .00013; for the chance of Group I scoring worst on 10 out
of 12 measures*) . Mean Change scores in Figure 3 suggest that the
placebo in Groups II and III was more effective in improving Anxiety,
Depression, Negative Affect, Perceived Stress Levels, Water Retention,
and Positive Affect than vitamin B6 in Group I. This trend is consistent
with the hypothesis that differential placebo effects occurred in this
study. The capsule form of placebo delivery used in Groups II and
III achieved a greater effect than the tablet form of vitamin B6
*Chance of 10 + chance of 11 + chance of 12 = 55 +12_ + J_ = .00013)
12 „12
3
12
administration in Group I. It is also consistent with the hypothes
that vitamin B6 is less effective in ameliorating premenstrual
symptoms than placebo in capsule form.
CHAPTER IV
DISCUSSION
In this dissertation, several goals were addressed: (1) to
determine whether dietary supplements of vitamin B6 can exert a
beneficial effect on premenstrual symptoms; (2) to develop a general
methodology suitable for studying the menstrual cycle; (3) to begin
the delineation of particular variables that warrant further
research; and (4) to develop a vigorously controlled method for testing
alternative treatments for premenstrual symptoms. A significant amount
of progress has been made toward each of these goals.
Data from this study indicate that vitamin B6 may improve premen-
strual symptoms under specific conditions which will be discussed
below. The hypothesis that vitamin B6 may exert beneficial effects
over time on physiological functioning and premenstrual dysphoria was
not supported by combined analyses of data from all three groups
studied. Nevertheless, a significant effect of vitamin B6 on improving
Poor Concentration was seen premenstrually in Group I. Also seen in
Group I were beneficial effects during the premenstrual phase of
vitamin B6 approaching significance on measures of Behavior Change,
Autonomic Symptoms, and Negative Affect. Similar effects on premen-
strual symptoms were not replicated in Groups II and III; however,
in Group II a significant effect of B6 on Poor Concentration was seen
during the luteal phase of cycle number two. In Group III, a significant
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effect of B6 was seen during the follicular phase of cycle number two
on Poor Concentration. Differences in the premenstrual phase findings
between Groups I, II and III cannot be explained by variations in
compliance, demographics, or baseline measurement levels.
Differential placebo effects could account for Group I differing
from Groups II and III. Perceptual characteristics of a placebo can
lead to differential levels of effectiveness, as well as differential
duration of placebo effectiveness. It is known that perceptual
characteristics of drug preparation can lead to changes in expectancies
regarding the efficacy of medications (Bukalew and Ross, 1981). Both
color and size of preparation can affect the expected drug action and,
therefore, its efficacy (Bukalew and Ross, 1981; Bukalew and Cof field,
1982a; Jacobs and Mordan, 1979). Capsule preparations were seen as
more powerful than a tablet, and white tablets, which resemble the
common aspirin (like that used in Group I)
,
are perceived as less
powerful than other colored tablets or capsules (Bukalew and Cof field,
1982a) . This finding is more pronounced among whites than among
blacks (Bukalew and Cof field, 1982b). The magnitude (and duration)
of placebo affect may have been increased in Groups II and III, both
of which received capsules rather than tablets, as in Group I. Data
from Mean Change score comparisons support the hypothesis that there
was a larger placebo effect in Groups II and III (see Figure 4) , and
in addition, that this effect was greater than the effect of vitamin B6
in Group 1 (see Figure 3). It is possible that a true effect of B6
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FIGURE 4. *Mean change scores between baseline and treatment
phases of the placebo condition. (Premenstrual
phase comparisons only)
. This figure illustrates
that in 10 cases out of 12, the placebo effect in
Groups II and III was greater in reducing symptoms
than that in Group I.
*A change in the negative direction indicates
improvement in intensity of premenstrual symptoms
in all measures, except positive affect.
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existed in all three groups, but was apparent only in Group I premen-
strually (see Figure 5) when compared to a relatively less effective
placebo due to its tablet form of preparation. A small true effect
of B6 in Groups II and III could have been overshadowed by a larger
magnitude placebo effect resulting from the use of capsules. Whatever
the case, data from this study indicate that a placebo in capsule
form is more effective than vitamin B6 in white tablet form. This
finding does not, however, rule out the possibility that physiological
variables play a role in the etiology of premenstrual symptoms. The
high placebo response rate in premenstrual research (Day, 1979;
Sampson, 1976; Steiner and Carroll, 1977) suggests that social-attitudi-
nal factors may play an important role in the development and expression
of premenstrual symptoms. It is also possible, however, based on the
physiological literature, that somatic factors play an equally large
role in influencing PMS . The most useful model for the study of PMS
is one that conceptualizes a complex, and perhaps circular, pattern
of interaction and feedback between psychological-social and physio-
logical variables, as it is likely that psychological and somatic
factors are inseparable and circular in their ability to influence one
another. To this author's knowledge, there has been no systematic
attempt to examime the true course and potential attenuation of
placebo responses compared to active treatment (Rubinov; and Roy-Byrne,
1984). Further research is warranted in order to assess the compara-
tive usefulness of vitamin B6 over placebo in treating premenstrual
symptoms, as a placebo in capsule form was more effective than
vitamin
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FIGURE 5
.
*Mean change scores compared between placebo and
B6 conditions in Group I. (Premenstrual phase
comparisons only.) This figure illustrates that
in Group I, vitamin B6 was more effective than
placebo in decreasing premenstrual symptoms
in 6 out of 12 variables.
*A change in the negative direction indicates an
improvement in intensity of premenstrual symptoms
in all measures, except positive affect.
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B6 in tablet form in this study.
The discrepancies between premenstrual phase findings in Group
I and Groups II and III might also be the result of stressful
seasonal events/holidays/final exams. Seasonal effects could
account for. cycle three differing from cycles one and two in Group I.
As discussed in the Results section, in Group I, cycle three, an
increase in Negative Affect, Poor Concentration, Behavior Change, and
Autonomic Symptons were seen premenstrually in the placebo condition,
but not in the vitamin B6 condition (see Figure 2). It is only
during the third cycle that B6 is more effective than placebo. Since,
for most subjects in Group I, the third cycle coincided with either
academic finals or Christmas/holiday events (see Figure 1) , it is
possible that vitamin B6 may have acted in a protective fashion during
stressful periods by preventing an increase in premenstrual dysphoria
which otherwise would have occurred. Indeed, data from this study
indicate that subjects in Group I were experiencing greater levels of
stress during the third cycle (see Results section) . Groups II and III
may have differed from Group I because treatment phases did not coincide
with stressful time periods. If vitamin B6 is only effective in a
"protective" fashion during times of increases stress, effectiveness
of vitamin B6 supplementation would not appear during less stressful
time periods such as those during which Groups II and III were run,
thus accounting for the discrepancies between Groups II and III and
Group I in this study.
7 b
It is thought that greater amounts of vitamin B6 may be utilized
by the body during stressful periods and it is a common recommendation
among lay people to use vitamin B complex supplements during times of
stress. However, to this author's knowledge, there have been no
studies directly assessing the effects of environmental/psychological
stressors on vitamin B6 status. It is known that psychological stress
can result in faster transit times through the stomach and small
intestine in humans (Cann, Read, Cammack
,
Childs, Holden, Kashman
,
Longmore, Nix, Simms, Swallow and Weller, 1983). Increased transit
times might result in decreased absorption of nutrients. The require-
ment for B vitamins might be increased when metabolism is speeded up,
as in muscular exercise, exposure to cold (Bourne, 1948-49), or
possibly in response to environmental stressors. Gyorgy (1938)
suggested that susceptibility to chilblains may be a function of
pyridoxine reserves in the body, and that supplementation with vitamin
B6 could aid in the prevention of chilblains. Changes in the status
of other nutrients in response to stress have been documented. Stress
is thought to alter the ratio of carnitines (a natural constituent
of animal tissue involved in lipid metabolism) , and it has been
postulated that exogenous carnitines may provide protection against
heart damage during periods of stress (Fanelli and Tenuta, 1981).
Vitamin B6 status may eventually be linked to increased susceptibility
to dysphoria during times of stress. Indeed, data from this study
suggest that vitamin B6 may ameliorate premenstrual symptoms,
specifically during times of stress.
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A separate, but equally interesting finding in this study, was
that vitamin B6 improved Poor Concentration levels in all three groups
of subjects studied. Interestingly, these changes occurred in
different menstrual cycle phases across groups. In Group I, vitamin
B6 improved concentration levels premenstrually ; in Group II, concen-
tration was improved in the luteal phase; and in Group III, it was
improved in the follicular phase of the cycle by vitamin B6 supplemen-
tation. It may be that concentration levels are more responsive to
vitamin B6 supplementation than mood or other physiological parameters.
Data from this study are consistent with the hypothesis that vitamin B6
may improve concentration levels regardless of menstrual cycle phase.
In summary, results from this study suggest that the beneficial
effects of vitamin B6 on menstrual symptoms include: 1) a general
overall ability to improve concentration levels regardless of menstrual
cycle phase, and 2) an ability to improve some premenstrual symptoms
(including dysphoria) during periods of increased stress. Ironically,
data from this study also suggest that a placebo in capsule form can
be more effective than vitamin B6 in tablet form in ameliorating
premenstrual symptoms.
Progress was made toward the development of a general methodology
suitable for studying the menstrual cycle and for testing alternative
treatments for premenstrual symptoms in a vigorously controlled
manner.
Most research on PMS , including the pilot version of this
dissertation,
has suffered from variability introduced by inaccurate
calculation of
menstrual cycle phase, seasonal changes, random life
events affecting
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within subject variability, age differences, and perhaps differential
responses from a variety of premenstrual symptom subtypes. This
study effectively avoided miscalculation of menstrual phases due tc
irregularities in cycle length by shifting periodic record keeping
to daily sampling through record keeping. The study also insured
that miscalculations did not interfere with proper timing of vitj
intake by providing daily supplements to subjects throughout the
entire treatment phase. The effects of seasonal weather changes
were controlled by running separate groups of subjects which overlapped
one month in participation over the academic year. Variation within
subjects which can be introduced by random life events was addressed
through increasing the number of subjects who were able to partici-
pate, by decreasing the length of time required for participation,
and reducing office visits to a minimum (one visit /month) . Subjects
were matched for age and type of symptom using a diagnostic criteria
developed by Steiner, Haskett and Carroll ( 1980) . Indeed, these changes
in methodology increased the number of women who participated in the
study (the sample sizes in each group of this study were larger than
others reported in the literature examining the effects of vitamin B6)
,
avoided entirely the possibility of miscalculating menstrual cycle
phases, and theoretically should have reduced any variability that
might result from differential responses from various premenstrual
symptom subtypes.
7 9
The process of delineating particular variables that warrant further
research was begun. Serendipitously
, the procedures used in this study
highlighted the importance of avoiding differential placebo effects
and controlling for the effects of emotionally stressful times of the
year as other factors which can introduce unwanted variability. Changes
in future research designs are indicated. Differential placebo
effects could easily be avoided by matching placebo preparation form
across conditions and groups. Use of a less effective form of placebo
(tablet) would be recommended in order to determine whether vitamin B6
supplements have any effect, regardless of the strength of that
effect and its clinical significance. The use of tablets would avoid
the possibility that subtle effects of vitamin B6 might be overshadowed
by larger placebo effects. Use of maximum strength form of placebo
(capsule) would be recommended in order to determine the clinical
significance of vitamin B6 treatment, or whether a placebo can be
equally or more effective than vitamin B6 . It would also be important
to run a parallel control group which received placebo and vitamin B6.
Seasonal effects, or the effects of emotionally stressful time
periods could be controlled by the use of a third No Treatment control
group, and through the use of more comparable subjects, i.e., only
students or only employed women. Replicating the study with systematic
timing of data collection would allow for comparisons to be made
between stressful periods and non-stressful time periods or seasons.
It would be important to include more careful and direct measures of
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stress levels. Ideally, subjects should be followed throughout the
entire year. Data collected during January, February and March, as
well as during June, July and August, would represent less stressful
periods (avoiding exams and holidays). Data gathered during June,
July and August would also avoid the potentially stressful winter
months. If an effect of season were found, further research comparing
the effectiveness of tablet versus capsule form of placebo and vitamin
B6 would be needed.
In general, it would be important to increase the length of baseline
measurements only if it were necessary to address variability between
cycles in symptoms, since a longer study would reduce the number of
subjects who would continue to completion, thus reducing the representa-
tiveness of any data gathered as it becomes more biased through
self -selection
,
i.e., only representing those subjects who are willing
to participate for longer periods of time.
This dissertation has determined that vitamin B6 may have a
beneficial effect on premenstrual symptoms during stressful periods of
time, and that vitamin B6 may improve concentration levels throughout
the menstrual cycle. It has also determined that a capsule form of
placebo may be more effective than vitamin B6 in tablet form in
treating premenstrual symptoms. Several improvements in methodology
introduced in this study have resulted in the ability to sample a larger
number of subjects and to minimize the introduction of unwanted
variability. A more rigorously controlled method for testing altern-
ative treatments for premenstrual symptoms has been developed, and
particular variables that warrant further research have been
delineated
.
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APPENDIX A
Samples of Forms and Questionnaires
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TELEPHONE SCREENING FORMAT
Caller
Caller's Age
Address
Where did she hear about this study?
Phone
NECESSARY POINTS TO MAKE :
1. The study will last 3 months and will involve daily record
keeping at home
.
2. Moods and menstrual symptoms will be monitored over those
months
.
3. It will involve coming to Tobin Hall once a month to turn in the
previous month's home records and receive additional home record
forms
.
4. They will be asked, after the first month, to take a dietary
supplement 3 times/day, with each mean, that will contain either
a supplement (such as a vitamin or mineral, not a drug) or a
placebo.
****Does she feel her premenstrual mood changes are moderate to
severe in nature????
INFORMATION TO COLLECT :
1. Age Must be between 25 and 40 (enter above also).
2. Is she on oral contraceptives?
3. Does she cycle regularly?
4. Any serious health problems, or regular medication that she
takes?
5a. Is she taking more than a multiple vitamin/mineral supplement
regularly?
5b. Does she take Motrin or Ponstel? Willing to go off
it?
6. Is she planning a pregnancy or planning to leave the area?
7. Do Friends or relatives notice her PM mood changes?
****IF SHE ANSWERS NO TO ALL OF THE ABOVE (except cycling
regularly)
,
THEN PROCEED
Interviewer
Call Number
Date
SCHEDULE AN INITIAL INTERVIEW
:
1. When is she expecting her next period to begin?
2. Schedule an appointment for her BEFORE it should begin.
3. Inform her that this appointment does not commit her or us
but that we will explain the study more fully and get more'
information from her at this time. She will be asked to
fill out some questionnaires and will be given home records
if she decides to participate.
Ask her for questions — repeat appointment time and sign-off****
INFORMED CONSENT FORM
I understand that in this study I will be asked to keep a regular
T
C
?
r
K- u
m
Ti
menStrUal SyTnptoms and mood changes, and that I will cometo Tobxn Hall once a month to have my home record keeping checked andto receive additional record keeping forms. I understand that after
a one month baseline period, I will be asked to take three capsulesdaily which may contain either a dietary supplement or a placebo(inert substance), which may or may not affect my menstrual cycle
symptoms. I understand that all of my records and all other
experimental data will be kept completely confidential and anonymous.
I understand that the dietary supplement and placebo represent no
risk to my health. I also understand that if I participate for 3
months, I will receive $10 to $25 for my participation. I have been
informed that I may withdraw my consent and withdraw from the study
at any time without penalty. I understand that although during the
study I will not be told what the dietary supplement is or whether
I will be taking a supplement or a placebo, at the conclusion of the
study I will be given all of this information as well as any other
information I wish to have about the methods and hypotheses of the study
Signature
Date
„ ,Printed Name
If you have any questions or problems, please call Kim Kendall at
545-1559 (W) or 586-0570 (H)
.
INITIAL INTERVIEW QUESTIONNAIRE
Date Name
Interviewer Subject //
Age Length of Cycle
Occupation Length of Menges
^
Approx. Income Educational level
General Dietary Habits
Please describe an average day's food intake in detail:
Breakfast Alcohol (ave/day)
Snack/ tea/coffee Total Caffeine (ave. // cups/day)
Lunch
:
Snack /tea/cof fee
:
Dinner
:
Vitamin/mineral Supplement
(describe in detail, include
amounts)
:
Medications/drugs (describe in
detail, include dosages):
Dessert / snack
:
Cigarettes (ave. ///day)
Menstrual Symptom Typology
When in your cycle do you experience
:
1. Menstrual symptoms (include length and onset):
2. Premenstrual symptoms (include length and onset), peaks? when?
abrupt end?
continued
.
would you describe your menstrual symptoms?
Primarily mood changes
Mild /mode rate /severe
Depression/anxious/irritable
Other
Primarily physical in nature:
Physical and Mood (BOTH)
:
How would you describe your premenstrual symptoms?
Primarily mood changes
Mild/moderate/severe
Depress ion /anxious /irrit ab le
Other
Primarily physical in nature:
Physical and Mood (BOTH)
:
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MOOS
Menstrual Questionnaire
Form A
Name Married Status
Age Number of Children
Today's Date Occupation
Write the approximate dates of your most recent menstrual period (flow)m the space marked "A" below. Then write the dates of the menstrual
period which preceded the most recent one in the space marked "D"
.
most recent flow
from other times during week before most from
to
m°st recent cycle recent flow to
On the next two pages is a list of symptoms which women sometimes exper-
ience. Please describe your experience of each of these symptoms during
the three different time period listed below:
during your most recent menstrual flow (the dates delineated
by area A on the diagram above)
,
during the one week before your most recent menstrual flow
(area B on the diagram)
during the remainder of your most recent menstrual cycle
(area C)
Note: The answers you put in columns 1, 2, and 3 should be accurage for
your experience specificaly during your most recent menstrual cycle.
Please do not simply report your general experience. Also, please report
any experience of these symptoms whether or not they seem to you to be
realted to your menstrual cycle.
Col. 1
Col. 2
Col. 3
Copyright
:
Rudolf H. Moos, 1968, 1977
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For each answer choose the descriptive category listed which bestdescribes your experience of that symptom during that time. Writethe number of that description in the space provided. Even if none ofthe descriptions are exactly correct, choose the ones that bestdescribe your experience. Do not leave any blank spaces.
Descriptive Categories:
1 - no experience of symptom 4 - present, moderate
2 - barely noticeable 5 - present, strong
3 - present, mild 6 - acute or partially disabling
1. 2 3
most week remainder
recent before of cycle
flow (A) (B) (C)
1
. Weight gain
2. Insomnia
3. Crying
4. Lowered school/work performance
5. Muscle stiffness
6. Forgetfulness
7. Confusion
8. Take naps or stay in bed
9. Headache
10. Skin disorders
11. Loneliness
12. Feelings of suffocation
13. Affectionate
14. Orderliness
15. Stay home from work/school
16. Cramps (uterine or pelvic)
17. Dizziness or faintness
18. Excitement
19. Chest pains
20. Avoid social activities
98
1 2 3
most week remainder
recent before of cycle
flow (A) (b) (C)
21. Anxiety
22
. Backache
23
.
Cold sweats
24. Lowered judgment
25
. Fatigue
26. Nausea or vomiting
27. Re stiessness
28. Hot flashes
29. Difficulty in concentration
30. Painful or tender breasts
31. Feelings of well-being
32. Buzzing or ringing in ears
33. Distractable
34. Swelling (abdomen/breasts/ankles)
35. Accidents (cut finger/break dish)
36. Irritability
37. General aches and pains
38 . Mood swings
39. Heart pounding
40. Depression (feeling sad/blue)
41. Decreased efficiency
42. Lowered motor coordination
43. Numbness or tingling in hands/feet
..
44. Change in eating habits
45. Tension
46. Blind spots or fuzzy vision
47. Bursts of energy or activity
In what ways, if any, was your most recent menstrual cycle unusual?
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Not for publication, use, or 7/1/81quotation without permission
PREMENSTRUAL ASSESSMENT FORM
(PAF)
Uriel Halbreich, M.D., Jean Endicott
,
Ph.D., & Sybil Schacht
, M.S.W.*
This form is used to describe changes which may occur during the pre-
menstrual period.
Instructions are on page 2.
Card No: ID No: Study No:
Date: Name or Initials
Education: (1) 15+ yrs; (2) 15 yrs; (3) 12-14 yrs; (4) 12 yrs
;
(5) 10-12 yrs; (6) 7-9 yrs; (7) 6 yrs or less
Degrees:
Occupation
(specify title, type of work, size of business, etc.)
Education of husband/mate
(use education code above)
Occupation of husband/mate
(specify)
Average number of days from one menstrual period to the next days.
If irregular, ranges from days to days.
If less than 21 days, reason: If more than 38
days, reason:
Average duration of premenstrual period days. Average duration of
blood flow days.
Still having menstrual periods: 1 - No 2 - Yes. If Yes, current
phase: 1 - During premenstrual period, 2 - During blood flow,
3 - During week after end of blood flow, 4 - Any other week _
Age at first menses: . Number of children:
Number of miscarriages/abortions:
Do you have mittelschmerz (ain in the middle of menstrual
cycle)?
1 - No 2 - Yes
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Special Conditions During Last Three Menstrual Cycles
Dysmenorrhea (pain when menstruating)
: l-No 2-Yes (describe)
Endometriosis (diaj;;nosed by doctor) : 1 -No 2-Yes (describe)
Take birth control pills : 1-No 2-Yes (specify type, how long
taking)
Have intra-uterine device: 1-No 2-Yes (specify type, how long using)
Use medication/home remedies to "treat" premenstrual changes:
1-No 2-Yes (specify type, reason)
Use any other medications: 1-No 2-Yes (specify type, reason, how long
using)
*New York State Psychiatric Institute and Department of Psychiatry,
College of Physicians and Surgeons, Columbia University, 722 West
168th Street, New York, NY 10032
Supported in part by NIMH Grants No. MH-30907 and MH-23864 and New
York Department of Mental Hygiene.
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Currently pregnant: 1-No 2-Yes (specify) months
Post menopausal: 1-No 2-Yes (how long) years months
Not menstruating for other reason: 1-No 2-Yes (specify reason)
Any medical disorder(s) currently present: 1-No 2-Yes (specify)
The physical, behavioral, and mood changes which take place during the
premenstrual period may be either positive or negative.
Please focus on the usual changes which have taken place during your
last three premenstrual periods, even if the changes did not last
throughout the entire premenstrual period.*
The premenstrual period may range from one to fourteen days. Each woman
should determine the duration of her premenstrual period using these
factors as guides. Physical, behavioral, and mood changes are consid-
ered to be part of the premenstrual period if:
(a) they appear or change during the premenstrual period;
(b) they do not exist in the same form or severity immediately
prior to the premenstrual period;
(c) they disappear or return to usual state during the full
flow or menses
INSTRUCTIONS
Think about the changes which you experience premenstrually . Consider
each item. Decide whether it describes a new condition or change which
usually has occurred during your last three premenstrual periods . Circle
the appropriate number to indicate the severity of change from your
usual state
For example, you may be anxious OR, if you are mildly
anxious most of the time, the anxiety may become more
severe. Either type of change should be noted.
DEFINITIONS OF THE RATINGS OF SEVERITY OF CHANGE FROM USUAL NONPREMEN
STRUAL STATE:
1 - Not applicable, not present at all, or no change from
usual level.
*Some studies may have special instructions which differ from these
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2 -
3 -
4 -
5 -
6 -
Minimal Change (only slightly apparent to you, other
would probably not be aware of change)
Mild Change (definitely apparent to you and perhaps
to others who know you well)
Moderate Change (clearly apparent to you and/or
others who know you well)
.
Severe Change (very apparent to you and/or others who know
you well)
.
Extreme Change (the degree of change in severity is so
different from your usual state that it is very
apparent to you OR even people who do not know you well
might notice)
.
1 - Not applicable, not present, no change, 2 - Minimal, 3 - Mild,
4 - Moderate, 5 - Severe, 6 - Extreme
Changes Present During Premenstrual Period
Have rapid changes in mood (e.g., laughing,
crying, happy, etc.) all within same day ..
Have decreased energy or tend to fatigue easily
Have decreased ability to coordinate fine
movements, poor motor coordination or
clumsiness
Feel anxious or more anxious
Sleep too much or have difficulty getting up
in the morning or from naps
Have a feeling of malaise (i.e., general, non-
specific bad feeling or vague sense of mental
or physical ill-health)
Feel jittery or restless
Have loss of appetite
Have pain, tenderness, enlargement, or swelling
of breasts 1
Have headaches or migraines
Be more easily distracted (i.e., attention shifts
easily and rapidly)
Usual Level of Change
During Last 3 Premen-
rual periods
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1 - Not applicable, not present, no change, 2 - Minimal, 3 - Mild,
4 - Moderate, 5 - Severe, 6 - Extreme
Changes Present During Premenstrual Period
Tend to have accidents, fall, cut self,
break things unintentionally
Usual Level of Change
During Last 3 Premen-
strual periods
Have nausea or vomiting
Show physical agitation (e.g., fidgeting, hand
wringing, pacing, can't sit still)
,
Have feelings of weakness
Feel that you just "can't cope" or are over-
whelmed by ordinary demands
Feel insecure
Have "flare-ups" of allergy, breathing difficul-
ties, stuffy feeling, or watery discharge
from the nose
,
Feel depressed
Have periods of dizziness, faintness, vertigo,
(room spinning), ringing in the ears, numbness,
tinkling of skin, trembling, lightheadedness ..
Tend to "nag" or quarrel over unimportant issues.
Think of what it would be like to do something
to self, like crash the car, wish to go to
sleep and not wake up, or have thoughts of death
or suicide
Feel less desire to talk or more about (it takes
an effort to do so)
Become more forgetful
Feel dissatisfied with personal appearance
Become more violent with people or things
(e.g., deliberately break things, hit someone) .,
Take naps during the day or have an overwhelming
desire to do so 1
Feel sense of unreality, like in a dream,
unreal , etc 1
Feel pounding of heart or have rapid heartbeat .
.
Get more, enjoyment or excitement out of little
things
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
5
5
5
5
6
6
6
6
6
6
6
6
6
6
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1 - Not applicable, not present, no change, 2 - Minixnal
,
3 - Mild
4 - Moderate, 5 - Severe, 6 - Extreme
Changes Present During Premenstrual Period
Have difficulty concentrating
Feel confused
Have lowered judgment (i.e., realize judgment
was less good than usual when looking back
on decision made during premenstrual period
Feel passive, want others to make decisions,
to take charge, etc
Have an increased feeling of well being
Have a lack of self control
Tend to become more childlike
Tend to feel or be tearful, weep, or cry
Feel need to urinate more frequently or have an
increased amount of urine
Become constipated
Tend to be self-indulgent in use of time,
spending money, eating, etc
Have episodes of impulsive behavior
Tend to smoke more, drink more alcohol or use
"drugs of abuse" (e.g., "pot," "speed," etc) ...
Feel under stress
Pick at, bite or scratch skin, or bite finger-
nails
Have mood swings from high to low or low to high
Tend to become "hysterical" if something
upsets you
Have guilt feelings
Feel "empty"
Have outbursts of "irritability" or bad temper .
Feel sad or blue
Have tired legs (weak, sore, tremble)
Usual Level of Change
During Last 3 Premen-
rual Periods
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
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1 - Not applicable, not present, no change, 2 - Minimal, 3 - Mild,
4 - Moderate, 5 - Severe, 6 - Extreme
Changes Present During Premenstrual Periods
Tend to have backaches, joint and muscle
pains or stiffness
Usual Level of Change
During Last 3 Premen-
rual periods.
Family or friends know "she is in one of her moods
today"
Feel "at war" on awakening or have complaints
or outbursts about old irritants
Act spiteful
Feel lonely ,
Urinate less frequently or in lesser amounts
Have weight gain
Tend to be intolerant or impatient or to lose
the ability to respond to or understand the
faults, needs or errors of others
Tend to be overtalkative
Have relatively steady abdominal heaviness,
discomfort or pain
Have increased sexual activity or interest
(fantasy, with self, with others)
Have trouble sleeping
Check, if wake early in morning and can't
get back to sleep
Have intermittent pain or cramps in the abdomen .
Have a decrease in self-esteem (i.e., don't
feel good about self or feel a failure)
Tend to blame others for problems (personal,
at home, work, school, etc.)
Have increase in activity, organization, effi-
ciency or involvement socially, at home or
work
Tend to brood over unpleasant events
Have skin problems such as acne, pimples, etc ...
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
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1 - Not applicable, not present , no change, 2 - Minimal, 3 - Mild,
4 - Moderate, 5 - Severe, 6 - Extreme
Changes Present During Premenstrual Periods
Have edema, swelling, puffiness, or "water
retention"
Stay at home more
Have less sexual interest or activity (fantasy,
self, others)
Tend to avoid social activities
Feel bloated
Usual Level of Change
During Last 3 Premen-
strual Periods
Have lowered performance, output, efficiency or
ease in tasks at work, at home, or with
hobbies, etc
Miss time at work because of premenstrual
changes
Want to be alone
Feel a lack of inspiration and creativity
Crave specific foods (sweets, bread, chocolate,
pickles)
Have an increase in appetite or tend to eat
more
Feel worse in the morning
Pay less attention to physical appearance
Feel cold and/or more sensitive to temperature
change
Have bursts of energy or feel more energetic
Become more sensitive to, or intolerant of, per-
sonal rejection of self or one's work
Feel more affectionate
Tend to seek advice more often, or about simple
matters
Have pessimistic outlook
Drink more coffee, tea, or cold drinks with
caffeine (cola, rootbeer, etc)
Feel pain or discomfort during intercourse
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
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1 - Not applicable, not present, no change, 2 - Minimal, 3 - Mild,
4 - Moderate, 5 - Severe, 6 - Extreme
Usual Level of Change
During Last 3 Premen-
Changes Present During Premenstrual Period strual Periods.
Do less housework (cleaning, care of
clothes, etc) 1 2 3 4 5 6
Spend less time at leisure activities (hobbies,
TV, reading) 1 2 3 4 5 6
Have "flare up" or appearance of cold sores,
diarrhea, belching, spontaneous bruises,
varicose veins, chest pain, hemorrhoids,
numbing, tingling, epilepsy ("fits"), sensi-
tivity of skin to sun (Specify ) ... 1 2 3 4 5 6
Have an increase in eye problems or changes
in vision (e.g., sty, redness, watering,
mistiness, discomfort, sensitivity to light) 1 2 3 4 5 6
In order to obtain a good comparison of your premenstrual state, as com-
pared to your usual state, it would be helpful to have a narrative
description of the differences, if any, between these two times.
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DAILY MOOD FORM
PMS 1982-83
Day of Cycle Participant
Date
Indicate how you feel today by marking along the line in the plac<
that best describes how you feel today. Do not spend too much time on
each statement, but give an answer which seems to describe your feelin
best Be sure to mark all dimensions.
1. Irritable Pleased
2. Outgoing Withdrawn
3. Not Lonely Lonely
4. Decisive Indecisive
5. Tired Energetic
6. Distracted Focused
7. Valuable Worthless
8. Full Empty
9. Helpless Powerful
10. Sad Happy
11. Downhearted Lightheart
12. Calm Tense
13. Content Worried
14. Nervous Confident
15. .Ti t-terv
Relaxed
Please rate how stressful your day has been:
16. Not al all
stressful
Extremely
stressful
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MENSTRUAL DISTRESS QUESTIONNAIRE
Form T
Name
Today's Date
On the next 2 pages is a list of symptoms which women sometimes
experience. For each symptom choose the descriptive category listed
below which best describes your experience of that symptom today.
Circle the number of the category which best describes your experience
of the symptom today
.
Even if none of the categories is exactly
correct, choose the one that best describes your experience. Please
be sure to circle one number for each symptom. Please also remember
to put your name and the date in the blank spaces at the top of this
page
.
Descriptive Categories:
1. No reaction at all 4. Present, moderate
2. Barely noticeable 5. Present, strong
3. Present, mild 6. Acute or partially disabling
1 . Weight gain
2. Insomnia
3. Crying
4. Lowered school or work performance
5. Muscle stiffness
6. Forgetfulness
7 . Confusion
8. Take naps or stay in bed
9 . Headache
10. Skin disorders
11. Loneliness
12. Feelings of suffocation
13. Affectionate
14. Orderliness
15. Stay home from work or school
16. Cramps (uterine or pelvic)
1 2 3 4 5 6
1 2 3 4 5 6
1 2 3 4 5 6
1 2 3 4 5 6
1 2 3 4 5 6
1 2 3 4 5 6
1 2 3 4 5 6
1 2 3 4 5 6
1 2 3 4 5 6
1 2 3 4 5 6
1 2 3 4 5 6
1 2 3 4 5 6
1 2 3 4 5 6
1 2 3 4 5 6
1 2 3 4 5 6
1 2 3 4 5 6
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1. No reaction at all 4. Present, moderate
2. Barely noticeable 5. Present, strong
3. Present, mild 6. Acute or partially disabling
17. Dizziness or faintness 1 2 3 4 5 6
18. Excitement
^ 2 3 4 5 5
19. Chest pains
^ 2 3 4 5 6
20. Avoid social activities 1 2 3 4 5 6
21. Anxiety
! 2 3 4 5 6
22. Backache 1 2 3 4 5 6
23. Cold sweats \ 2 3 4 5 6
24. Lowered judgment 1 2 3 4 5 6
25. Fatigue 1 2 3 4 5 6
26. Nausea or vomiting 1 2 3 4 5 6
27. Restlessness 1 2 3 4 5 6
28. Hot flashes 1 2 3 4 5 6
29. Difficulty in concentration 1 2 3 4 5 6
30. Painful or tender breasts 1 2 3 4 5 6
31. Feelings of well-being 1 2 3 4 5 6
32. Buzzing or ringing in ears 1 2 3 4 5 6
33. Distractable 1 2 3 4 5 6
34. Swelling (e.g., abdomen, breasts, ankles) 1 2 3 4 5 6
35. Accidents (e.g., cut finger, break dish) 1 2 3 4 5 6
36. Irritability 1 2 3 4 5 6
37. General aches and pains 1 2 3 4 5 6
38. Mood swings 1 2 3 4 5 6
39. Heart pounding 1 2 3 4 5 6
40. Depression (feeling sad or blue) 1 2 3 4 5 6
41. Decreased efficiency 1 2 3 4 5 6
42. Lowered motor coordination 1 2 3 4 5
43. Numbness or tingling in hands or feet 1 2 3 4 5 6
44. Change in eating habits 1 2 3 4 5 6
/c m - ..12345645 . Tension
46. Blind spots or fuzzy vision 1 2 3
4 5 6
47. Bursts of energy or activity 1
2 3 4 5 6
APPENDIX B
Sample of Post-Study Questionnaire and Follow
Letter Sent to Participants
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POST
-STUDY QUESTIONNAIRE
Participant
1. Keeping self -observation records often has an effect on people's
feelings and behavior. What was your reaction to keeping
records? Did it many any changes in your moods or activities?
2. Were your menstrual cycles, while you were participating in the
study, typical for you, or different? How different? Which
cycles were different?
3. Did you make any major changes during the study, or did anything
major happen to you? (moved, married, separated, etc.)
4. Would you be willing to take part in a similar study again. If
so, what suggestions for changes would you make for the study,
in terms of questionnaires and other procedures.
5. Did you notice any changes in your feelings or behavior when you
started taking the pills? What were the changes and when did you
experience them?
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FOLLOW-UP LETTER SENT TO PARTICIPANTS
Dear Participant:
The Premenstrual Study research team would like to thank you for
your time and effort which have contributed so greatly to the success
of our project. The confidential information which you have given us
has been combined with information from other participants. The
meaning of the results of our study is still unclear at this point.
We studied three separate groups of women. Half of each group
received B6 and half received a placebo supplement. Only in the first
group of women did vitamin B6 show a significant effect in lowering
premenstrual depression and increasing concentration. No effects were
seen in the 2nd and 3rd groups of women we studied. It is possible
that the women in our 2nd and 3rd groups received an expired or less
potent vitamin B6 supplement than those in the 1st group. The vitamin
B6 received by women in groups 2 and 3 is currently being reassayed
for potency and these results are not yet in.
Unfortunately, all of this means that we cannot be sure that vitamin
B6 did have a greater effect than placebo supplements on lowering
premenstrual depression in our study. It seems to have done so in our
1st group and we are currently trying to understand why our results
differed for the 2nd and 3rd groups of women who participated earlier
this year.
Enclosed you will find a check for $12.00 as a small token of our
appreciation for your participation in our project. Also enclosed is
a graph of your individual data on a number of variables which we
measured over 3 menstrual cycles. We have divided each of your 3
cycles into 5 phases and taken an average score for each phase and
plotted this on the graphs which are enclosed. There are 15 points on
each graph, representing 3 months divided into 5 phases each. On the
graph these phases are represented with "M, 2, 3, 4, P :
M - menstrual phase
2 - luteal phase
3 = ovulatory phase
4 = follicular phase
5 = premenstrual phase
Each graph represents a different variable and the scale
on each
graph differs, so that it is not possible to make comparisons
between
two different measures. It is possible to note whether
your level of
any single measure (i.e., depression) varies over the
month, or varied
from the 1st month (or baseline period) to the 3rd month
<jr tod«Bth
on the vitamin or placebo). Remember that Month 1
(the 1st 5 points
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on each graph) was baseline only. The placebo or vitamin was takenduring months 2 and 3 (the 6th - 15th points on each graph) Also
remember that it is difficult to understand what your graphs may mean,
since your scores were affected by many other things besides the
vitamins or placebos, such as external events, stress, weather, and
what have you
.
Most of the labels on the graphs are self-explanatory, but some
are unclear.
All Neg. Affect
Percv. Stress
Menstr. Pain
Poor Concen.
Autonom. Symp
.
H
2
0 Retent'n,
Neg. Aff. Moos
Pos. Aff. Moos
Lack of Cont
.
- a combined score of depression and
anxiety
= the amount of stress you perceived
in your life each day
= menstrual pain, cramps, backache, etc.
= decreased concentration
= autonomic symptoms, such as dizziness,
insomnia, nausea, etc.
= water retention, swollen breasts, weight
gain, etc.
= Negative affect on the every-other-day
form; includes depression, irritability,
and anxiety
= Positive affect on the every-other-day
form; feeling of well-being, affectionate,
excitement, etc.
= Lack of control
Please write to me at the address below if you have further questions
regarding the study. The final write-up will be available in the
Psychology Department Library (Tobin Hall) later next spring if you are
interested in seeing it. (Because of the bulk and cost of this write-up,
it will not be sent to participants.)
Again, we want to thank you very much for your time and patience!
Sincerely
,
Kim Kendall, M.S.
Director, PMS Research Project
and the PMS Research Team
KK/jb

